

South Carolina Commission on Higher Education

December 21, 2018

Members of the General Assembly and Department of Administration:

Included in this correspondence are comprehensive drafts of the 2017-18 SmartState[®] Audit and Annual Report. On November 30, 2018, the SmartState[®] Review Board requested an extension for submission of the SmartState[®] annual report and audit until Friday, December 21, 2018. The audit is complete and has been thoroughly vetted and re-vetted by the Atlanta-based CPA firm of Maulden & Jenkins, LLC's governmental auditing, accounting, and reporting expert. At its December 21st meeting the SmartState[®] Review Board approved the final draft of the SmartState[®] Audit and Annual Report. However, for report distribution the leadership of the three research universities must sign the final audit report and financial statements. As you can imagine, coordinating signatures from the research institutional representatives including presidents and financial officers, during holiday travel season has not been possible. The institutions have assured us of receipt of the report and audit, and of the presidents and officers' signatures as soon as they return in early January. Until then, in order to meet the December 21st deadline, we are sending this version approved by the SmartState[®] Board, and again, we'll procure institutions' signatures and transmit that version once we have it.

Please contact Dr. Argentini Anderson at (803)737-2276 or <u>aanderson@che.sc.gov</u> if you have any questions.

Thanking you in advance.

Sincerely,

/s/ Argentini Anderson

Argentini Anderson SmartState[®] Program Administrator

SmartState Centers of Economic Excellence

2017/2018 ANNUAL REPORT



Contents

- 2 Mission
- 3 SmartState Review Board
- 5 South Carolina's Research Universities
- 6 AACR Honors Doctor Chanita Hughes Halbert
- 7 Dr. Kevin Huang received the "2018 Breakthrough Leadership Award"
- 8 SmartState ROI and By The Numbers
- 10 Investors, Startups and Relocations
- 11 Clemson, MUSC OR Design Project
- 12 #STEMlikeagirl
- 13 SmartState Centers and Endowed Chairs
- 23 The sky is not the limit
- 25 SmartState Program Endowed Chairs
- 29 Cancer biologist leads team in unraveling cellular activity
- 30 SmartState Program Contacts



MISSION: The South Carolina SmartState® Program serves the public interest by creating incentives for the state's research universities, in cooperation with other institutions of higher education in the state, to raise capital from non-state sources to fund endowments for specialized research professorships. These professorships in turn serve as the nucleus for unique, university based research centers which cultivate critical, public-private industrial partnerships, expand the state's knowledge base, create well-paying jobs, enhance economic opportunities, and improve the quality of life for the people of South Carolina.

SmartState Review Board

The SmartState Review Board consists of eleven members who serve three-year terms.

Three are appointed by the Governor,

Three are appointed by the President Pro Tempore of the Senate,

Three are appointed by the Speaker of the House of Representatives,

One by the Senate Finance Committee, and

One by the Chairperson of the House Ways and Means Committee.

The Review Board oversees operations of the SmartState® Program. The presidents of South Carolina's three research universities serve as ex officio, non-voting members.





JASON P. PREMO CHAIR Appointed by the Governor



CHARLES KEREKES VICE CHAIR Appointed by the Governor



CHARLES W. GARNETT Appointed by the Governor



LISA D. MAIN Appointed by the Speaker, House of Representatives



ROBERT W. PEARCE, JR. Appointed by the Speaker, House of Representatives



REGAN VOIT Appointed by the Chairman, Senate Finance Committee



MELVIN C. WILLIAMS Appointed by the President Pro Tempor, Senate



ROBERTA BANKHEAD WOOD Appointed by the Chairman, House Ways & Means Committee

The SmartState® Program does not receive taxpayer dollars to fund economic development-related initiatives to benefit the state. It is funded through revenue generated by the South Carolina Education Lottery, which is then matched dollar-for-dollar by non-state businesses and foundations.



JAMES P. CLEMENTS, Ph.D.
President
Clemson University



DAVID J. COLE, M.D., FACS
President
Medical University of South Carolina



HARRIS PASTIDES, Ph.D. President University of South Carolina

In 2002, members of the South Carolina General Assembly recognized the critical role research universities have in advancing innovation, creating economic and educational opportunities, and improving overall quality of life for the state's citizens when it acted by the enabling legislation of the SmartState Program. Today, other states look to South Carolina's SmartState Program as the model for university-based public-private partnerships that foster innovation, launch companies and create jobs.

Ranked #23 among national public universities, **Clemson** is a major land grant, science- and engineering-oriented research university that is an inclusive, student-centered community characterized by high academic standards, a culture of collaboration, school spirit, and a competitive drive to excel. With agricultural and forestry research centers and innovation campuses located from Greenville to Charleston, and a presence in every county, Clemson's campus is truly the entire state of South Carolina. This year, Clemson was classified among universities with the highest level of research activity by the Carnegie Classification for Institutions of Higher Education.

Clemson has launched a new strategic plan, Clemson Forward, which emphasizes high-impact engagement opportunities to prepare students for a knowledge-based global economy, and growing research and doctoral education to help find solutions to real world problems. The plan also supports economic development and creates jobs, enhances quality of life and builds the university's national academic reputation. The plan identifies six innovation clusters to support development of multi-disciplinary teams and large research projects: Health Innovation, Sustainable Environment, Human Resilience, Big Data Science, Complex Engineered Systems, and Advanced Materials.

MUSC has served the citizens of our state since 1824. MUSC has expanded from a small, private college to a comprehensive academic health sciences center, with more than 1,700 faculty members educating and training more

than 3,000 students, residents, and biomedical scientists in six colleges (Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing, and Pharmacy). As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of \$2.3 billion, with an annual economic impact of more than \$3.8 billion and research funding in excess of \$250 million annually. MUSC Health operates one of the state's largest and most innovative health systems, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I Trauma Center, Institute of Psychiatry, and the state's only transplant center.

Since opening in 1805 with an initial enrollment of nine students, the University of South Carolina (USC) has grown its student body to more than 50,000 across eight campuses statewide. USC, the fourth fastest growing flagship university in the nation boasts 47 nationally ranked programs by U.S. News & World Report. The main campus in Columbia offers more than 300 degree programs through its 14 colleges and schools, which include the Darla Moore School of Business, the School of Law, the Arnold School of Public Health, and the nation's top-ranked public university honors college. USC is also one of only 32 public universities to receive the top-tier research designation and the top-tier community engagement designation from the Carnegie Foundation. As a leader in health sciences, USC offers the most comprehensive suite of health science academic programs (100) in South Carolina, including medical schools in Columbia and Greenville. That diversity of offerings allows for expansive research opportunities as well as exemplary student experiences, which have made the South Carolina the state's top global university. The university's strength in leading-edge research has led to recent public/private partnerships with Fortune 500 companies like Fluor, IBM, Siemens and Boeing. And, USC's 19 locations and its alumni throughout South Carolina pump \$5.5 billion into the state's economy annually, making Carolina an indispensable contributor to the state's prosperity.

MUSC MEDICAL UNIVERSITY of SOUTH CAROLINA

AACR Honors Doctor Chanita Hughes Halbert



Dr. Hughes-Halbert is the first woman and first African-American from South Carolina elected into the National Academy of Medicine. Image Credit: Emma Vought

Hollings Cancer Center researcher Chanita Hughes-Halbert, Ph.D., is the recipient of the 2018 AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by the Susan G. Komen organization, the American Association for Cancer Research (AACR) announced today.

The AACR Distinguished Lecture on the Science of Cancer Health Disparities recognizes an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment or prevention of cancer health disparities.

Hughes-Halbert said she's honored to have been chosen. "This important award brings attention to the research and scholarship that is being conducted to enhance cancer equity in racial and ethnic minorities and individuals from other medically underserved groups," she said. "My topic, which will address the ways in which social and psychological factors contribute to disparities, can be used to promote effective behavior and clinical changes to promote equity."

Hughes-Halbert is the principal investigator and director of the Transdisciplinary Collaborative Center in Precision Medicine and Minority Men's Health at Hollings Cancer Center at the Medical University of South Carolina (MUSC). In addition, she is the associate dean of assessment, evaluation and quality improvement and a professor in the Department of Psychiatry and Behavioral Sciences at MUSC. She also holds the AT&T Distinguished Endowed Chair for Cancer Equity at Hollings Cancer Center at MUSC.

The AACR is recognizing Hughes-Halbert for her research aiming to identify sociocultural, psychological and behavioral determinants of cancer disparities and to translate this evidence into interventions to improve cancer outcomes in medically underserved populations. Within this overarching program, her research focuses on three converging lines of investigation that have high clinical and policy importance: enhancing the participation of minorities in cancer research, developing culturally tailored assessments and interventions to improve cancer outcomes in minorities, and developing a sustainable infrastructure for cancer prevention and control through community-based participatory research methods.

Notably, her research has defined the field of genetic counseling and testing for inherited breast cancer risk in African-American women, and she was the first to examine acceptance rates and outcomes of genetic counseling and testing for BRCA1/2 mutations among African-American women. Her research in genetic counseling and testing provided a model of culturally tailored strategies for cancer prevention and control among racial minorities.

More recently, Hughes-Halbert has conducted translational research to understand the complex ways in which sociocultural, psychological, behavioral, genetic and clinical factors interact to produce racial and ethnic disparities in health care and disease outcomes among minority men. Her evolving research in this area has demonstrated that a willingness to participate in precision medicine studies is limited among African- Americans despite having positive expectations about the benefits of personalized medicine.

Hughes-Halbert is a past chair of the AACR Minorities in Cancer Research Council and currently serves on the editorial boards of Cancer Epidemiology, Biomarkers and Prevention and Cancer Prevention Research, two scientific journals of the AACR. She has been a member of board of scientific advisors at the National Cancer Institute and the National Advisory Council for the Human Genome Research. The National Academy of Medicine elected her to its ranks in 2017, making her the first investigator and woman in South Carolina to earn this distinction. She received a bachelor's degree from Hampton University and both a master's degree and doctorate in personality psychology from Howard University.

The AACR honored Hughes-Halbert during the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2 through 5, in New Orleans. She delivered her award lecture, "Toward Understanding Psychosocial and Behavioral Issues in Cancer Health Disparities," on Friday, Nov. 2.



Dr. Kevin Huang has received the "2018 Breakthrough Leadership Award" from the University of South Carolina, Office of Research.

In the eight years Kevin Huang has been at the University of South Carolina, the energy science researcher has established a worldclass electrochemical energy materials laboratory and program.

As a mechanical engineering professor and chair of the SmartState Center for Solid Oxide Fuel Cells, Huang's research is aimed at developing efficient, clean and low-carbon energy conversion and storage technology for a sustainable future. His work is directed toward electrochemical-energy materials science and engineering for fuel cells, rechargeable batteries and gas-separation membranes. Toward this end, he has authored more than 160 peer-reviewed papers and two books and has received 12 U.S.-issued patents, five from his research at USC.

His research has resulted in significant external funding, totaling more than \$6.5 million from agencies including the National Science Foundation, the Department of Defense and the Department of Energy. The Advanced Research Projects Agency-Energy award has helped increase USC's visibility as a major research university.

"The ARPA-e award is the first in USC history. That fact that Dr. Huang leads teams from the University of Texas at Austin, University of Maryland, Clemson and Atrex Inc. demonstrates his outstanding leadership in the field," says Jamil Khan, professor and chair of mechanical engineering in the College of Engineering and Computing.



"Mentoring new junior faculty to accommodate the unique departmental culture is extremely important in fostering productive interdisciplinary collaborations among junior and senior faculty." - Kevin Huang

In 2017 Huang received the Educational Foundation Award for Research in Science, Mathematics and Engineering and in 2015 the College of Engineering and Computing Research Achievement Award. In 2014, he was named a Breakthrough Star by the Office of the Vice President for Research. Huang also has been actively involved in helping new and junior faculty members to start their programs and labs.

"The department of mechanical engineering is a multidisciplinary academic unit consisting of disciplines in conventional mechanical engineering, nuclear engineering, aerospace engineering and materials science engineering," Huang says. "Therefore, mentoring new junior faculty to accommodate the unique departmental culture is extremely important in fostering productive interdisciplinary collaborations among junior and senior faculty."

SMARTSTATE® PROGRAM:

Return on Investment

The primary mission of the SmartState* Program is to generate high-skilled, highwage jobs in South Carolina.

Through establishing research centers that (1) expand the state's knowledge base, (2) create public-private partnerships, (3) support startup firms, and (4) help retain highly talented workers, the SmartState Program actively supports the ongoing development of the knowledge economy - and jobs in the knowledge economy are among the highest paid of all industries in South Carolina. The creation of high-wage jobs across the state is especially important in the current economic environment in which wage growth has been relatively mild despite a national economic expansion that is now in its tenth year.

In general, professions within the knowledge economy are highly technical and typically require extensive academic training in mathematics and science as well as the ability to engage in complex problem solving. Tasks are often both theoretical and practical, combining the creative skills necessary for innovation and technological development with the practical knowledge of commercializing new ideas, which is what leads to regional economic growth and development. The intellectual talents required for jobs in these professions are highly sought after across the world, and regions with high concentrations of these professions generate enormous human capital resources and knowledge spillover effects.

As of 2018, the SmartState Program is responsible for helping to create and support approximately 14,626 jobs in South Carolina, which is associated with over \$2.8 billion in economic activity and \$807 million in labor income for South Carolinians that would not exist otherwise. Approximately 5,616 (38%) of these positions are knowledge economy jobs created directly through the SmartState Program, with the remaining 9,010 (62%) arising from additional spending activity generated through the economic multiplier effect.

"Despite the fact that the current economic expansion is now in its tenth year, wage growth remains relatively sluggish in both South Carolina and the United States. One critical factor that will help combat this trend in the Palmetto State is the continued growth of a strong and vibrant knowledge economy. Since 2002, the SmartState Program has helped to facilitate the development of the knowledge economy in South Carolina and in the process has generated over 14,000 jobs with annual salaries that pay significantly above the state average."

DR. JOSEPH VON NESSEN Research Economist Darla Moore School of Business, University of South Carolina



- 1 Industry-focused research is conducted in six areas of global importance: Advanced Materials and Nanotechnology, Automotive and Transportation, Biomedical, Energy, Information Science, and Pharmaceutical.
- $2 \quad Includes \$180 \ million \ from \ the \ State \ Education \ Lottery \ appropriations \ and \$17.6 \ million \ accrued \ interest \ from \ Smart \ State \ Program \ endowment.$
- 3 The figures reported are from the November 2018 Economic Impact of the SmartState® Program analysis conducted by the Darla Moore School of Business. Of the total 14,626 jobs, 5,616 are knowledge economy jobs created directly through the SmartState® Program, including 592 SmartState personnel, 1,287 start-up company and corporate relocation personnel, 33 alumni placed with in-state employers, and 3,737 employed through Extramural Research Funding. The remaining 9,010 jobs are indirect employment arising from the economic multiplier effect. For more information about the return on investment, see page 12.
- 4 See page 10 for a listing of investors, start-ups and corporate relocations.

Investors, Start-ups, and Corporate Relocations in SC

CORPORATE AND ORGANIZATIONAL INVESTORS

More than three dozen companies have invested \$500,000 or more in the SmartState* Program.

- · Abney Foundation
- BASF
- · Bank of America Foundation
- · Biomass Gas & Electric
- BlueCross BlueShield Foundation of SC
- · BMW
- · Comporium Group
- · Daniel Island Company
- · Dialysis Clinics, Inc.
- · Duke Energy
- · Duke Energy Foundation
- Electric Cooperatives of South Carolina
- · Fluor Corporation
- · Force Protection Industries
- · G. E. Renewable
- · General Atomics
- · George B. Sibert Annuity
- · GlaxoSmithKline
- · Greenville Hospital System
- · Health Sciences South Carolina
- · J.E. Sirrine Foundation
- · Kellogg Foundation
- Kentwool
- · Michelin
- · Okuma
- · Orbis
- · Palmetto Health
- · PalmettoNet
- · Research to Prevent Blindness
- · Robert Wood Johnson Foundation
- · Samuel Freeman /
 - Donaldson Charitable Trust
- · Santee Cooper
- · Smith & Nephew
- Spartanburg Regional
- SRNL
 - Healthcare System
- · The Duke Endowment
- · The Spaulding Paolozzi Foundation
- Timken
- · Toyota
- Volvo
- · Westinghouse
- ZF

START-UP COMPANIES

Start-up companies founded as a result of research at USC, MUSC, and Clemson University:

- · Advanced Photonic Crystals
- · Career Care Solutions
- Cephos
- Cicadia
- Clinacuity
- · Closing the Gap in Healthcare, Inc.
- Coastal Focus Market Research Company
- · DF Werke, LLC
- · Doxy.me
- · eCAM
- · Fibro Therapeutics, Inc.
- · First String Research
- · GeoMat, LLC
- · Hydrogen Hybrid Mobility, LLC
- · ImmoMod, Inc.
- · Inquisatex Epitherapeutics, LLC
- · IntrusinMyFamily.com
- · MagAssemble, LLC
- · MicroVide
- · MitoChem Therapeutics, LLC
- · MitoHealth
- · Neuroene Therapeutics
- · NextGenEn
- · NXT
- · Oncology Analytics
- · Palmetto Fuel Cell Technologies,
- · Palmetto Green
- · Parallel Permeation, Inc.
- · Patient Guided Health Solutions,
- · Perfect Mixing, LLC
- · Protara, LLC
- SAGE Energy Solutions
- · Schnellgen, Inc.
- · SemiAllogen, Inc
- · SimTunes, LLC
- · Smart Innovations, LLC
- · South Carolina Science Solutions,
- · Specialty & Custom Fibers, Inc.
- · Tetramer Technologies
- · Vortex Biotechnology
- · Zeriscope, Inc.
- · 52 Inc.

CORPORATE RELOCATIONS

Companies that have relocated to South Carolina to benefit from the expertise, resources, and graduates in the SmartState® Program:

- · A. Berger
- American Titanium Works (ATW) Manufacturing
- American Titanium Works (ATW)
 Technology Center
- BMW Information Technology Research Center (ITRC)
- · CADFEM U.S.
- · Charge2Target
- · CleanEnergy
- · COE Optics
- Computech*
- · Cooliemon Technologies*
- · C-P-S Group
- · DreamWeaver*
- · EHD Tech
- · Environment and Health Inc. (EHG)
- Esys Automation
- · Fields Group, LLC.*
- · Focus Chemicals*
- · FSI Advanced Research
- Greenway Energy, LLC
- · In-tech
- · Innoventure
- IndvSoft
- · Intec U.S. Inc.
- · Intellectual Capital Group
- · International Mold Co.
- · JTEKT Technology Center
- Mallet Technology*
- · Michelin
- · Michelin Incubator
- Mumford Industries*
- OmniSource
- · Proterra, Inc.
- · RESA (AIG-Clemson)
- Dadina*
- · Sage Automotive Interiors*
- · SC Research Authority (SCRA)
- · Senex Biotechonology, Inc.
- · Simpack, Inc.
- · SWJ Breilman
- · ThermoPur Technologies*
- Tigges*
- · Toho Tenax*
- · Trulite

In May 2012, CU-ICAR (Clemson University International Center for Automotive Research) opened the doors to the Center for Emerging Technologies (CET) facility, its first multitenant building. CET provides office, administrative, and laboratory space for transportation, technology, and energy sectors. These companies have positioned themselves on the CU-ICAR campus to be close to the SmartState Endowed Chairs and their research teams.





Clemson, MUSC share gains made in OR design project "Show and tell" of innovative design demonstrates future impact

CHARLESTON S.C. - A joint research team including faculty from Clemson University and the Medical University of South Carolina (MUSC) unveiled a high-fidelity, mockup operating room (OR) at the Clemson Design Center in Charleston today. The prototype is based on three years' worth of research of past literature on OR functionality; observation of best practices in updated, modernized ORs; and input from nurses, doctors and anesthesiologists on how the new OR should function.

Lead investigators on the joint MUSC-Clemson project titled, "Realizing Improved Patient Care Through Human-Centered Design in the OR" (RIPCHD.OR) are Scott T. Reeves, M.D., the John E. Mahaffey, M.D. endowed chair and MUSC Department of Anesthesia and Perioperative Medicine chairman, and Anjali Joseph, Ph.D., the Spartanburg Regional Health System endowed chair in architecture and director of the Center for Health Facilities Design and Testing at Clemson University.

The goal of RIPCHD.OR is to analyze every aspect of the current OR standard and redesign it with efficiency and improved patient care in mind. Surgical leaders from the South Carolina Surgical Quality Collaborative, led by Mark Lockett, M.D., will help vet the group's findings.



Joseph and Reeves during the Jan. 25 unveiling of RIPCHD. OR in Charleston.

Image Credit: MUSC photo

"We've taken a comprehensive, evidence-based approach to redesigning operating rooms to create an evidence-based design solution that simultaneously tackles problems related to workflow, equipment design and the built environment – major areas that impact patient safety outcomes," Joseph said.

The new operating room design aims to:

- improve staff safety by reducing clutter and trip hazards;
- reduce surface contamination through material selection and improving ergonomics;
- support team communication by refining sightlines and visibility within the OR; and
- adapt as care delivery and technology change without significant cost or disruptions through use of modular wall panels. The team of researchers, engineers and clinical specialists involved in this project received a four-year, \$4 million research grant from the Agency for Healthcare Research and Quality in 2015 to research and develop a safer, more efficient OR.

"We want to establish a new standard on what should be considered when you build an OR, and the first two years of this project have been dedicated to that end," Reeves said. "Now in our third year, we've designed and constructed a simulation of this future state OR, complete with mannequins and software that will enable comprehensive testing of the design. It's exciting to be at this point in the project, and we are eager to start collecting more data and feedback."

Most ORs across the nation consist of a cramped, square white room with a patient bed in the middle of the space; they are antiquated, confined spaces that do not accommodate today's high-tech surgical equipment, complex processes and human interactions. Distractions and interruptions are major causes of errors during surgery and often lead to patient harm. Additionally, up to five percent of patients who undergo surgery will develop a surgical site infection. Smarter, evidence-based design has the potential to make operating rooms safer for patients and health care personnel alike.

"The standard OR does not support the needs of the patients, nurses or surgeons, so we're excited to have reached the testing point for these new concepts and to demonstrate what we've learned through this mock OR and simulation experience," Joseph said. The first-of-its-kind project covers three specific areas of research designed to improve patient care and efficiency in a future OR design: unmasking of anesthesia-related alarms and communications, traffic flow and door openings, and an integrated OR suite design. The design and fabrication of the prototype room was developed by a team of graduate students in the Architecture + Health program at Clemson under the direction of Alumni Distinguished Professor David Allison, in collaboration with the research team, MUSC clinicians and industry partners.

Reeves and Joseph agree — this groundbreaking project would not have become a reality without multidisciplinary, collaborative forces teaming up to improve patient safety and care. "When institutions of excellence align their interests and work together to achieve a common goal, patients win," Reeves said. "It has been a really wonderful relationship between Clemson and MUSC that has made this all possible," Joseph explained. "We have the researchers, expertise and the manpower to do all of this, and MUSC has the leadership and know-how it takes to implement it."

#STEMlikeagirl

MUSC women scientists give girls a taste of science careers Leslie Cantu | cantul@musc.edu

Research is fun.

That's the message that Carol Feghali-Bostwick, Ph.D., and devoted women volunteers wanted girls to get at a recent STEM-oriented camp at the College of Charleston. STEM stands for science, technology, engineering and math.

And the girls did have fun. Outfitted with lab coats and gloves, they mashed up bananas into a simple solution of materials found around the house and extracted the banana DNA. They even got a banana DNA-extraction recipe to take home so they could replicate the experiment with family and friends.

The free three-day camp, called Girls Day Out, included participation from many STEM-oriented industries around the Lowcountry, including Bosch, Boeing, Nucor, Google and the Space and Naval Warfare Systems Command (SPAWAR).







Camp participants conducted a simple experiment. Courtesy of Girls Day Out

Because of Charleston's mix of industries, most people here tend to think first of technology and engineering when they think STEM, but the MUSC group from the Women Scholars Initiative, College of Medicine Center for ARROWS and SCTR showed the girls that science is a viable career as well. Not only did the girls get to do a hands-on activity, but they got to meet women scientists – every person leading the activity was a woman, each with a Ph.D.

Feghali-Bostwick, the SmartState and Kitty Trask Holt endowed chair and Professor of Medicine in the Division of Rheumatology and Immunology, said she wants girls to see research science as an attainable goal. Girls Day Out was geared toward girls entering eighth and ninth grades –the ages when interest in science tends to drop off for girls, according to studies.



Camp participants conducted a simple experiment.

Courtesy of Girls Day Out

"That's the age where they start questioning if they can do it," said Feghali-Bostwick, who also serves as chair of the Women Scholars Initiative.

She credited the new WSI community outreach committee, chaired by Kristine DeLeon-Pennell, Ph.D., with organizing the banana DNA extraction activity. Lindsay McDonald, Ph.D.; Lillianne Harris Wright, Ph.D.; Iuliia Polina, Ph.D.; Diana Lee-Chavarria, education program manager at SCTR Institute;, and Rachel Simmons, WSI and Center for ARROWS program coordinator, worked the event while Daria Ilatovskaya, Ph.D., also helped with planning.

The girls got to take home some MUSC swag, including cute pens with a hashtag that reminds them to #STEMlikeagirl.

The committee wants to do more to introduce girls to research science. Talks are in progress about developing programming with the Girl Scouts or in local schools.

SMARTSTATE® PROGRAM Centers And Endowed Chairs

The work of South Carolina's SmartState Centers is exciting, groundbreaking, and of critical importance to the state, nation and world. These Centers, which align with industries in South Carolina, help elevate the state's economy and quality of life. What follows is an overview of each Center.

Program totals reported as of November 2018. In cases of joint proposals, Centers awarded by an institution are tallied by the fiscal agent. Endowed chairs are tallied based on the assigned institution. USC's assigned endowed chairs include one joint appointment with MUSC and Clemson. On the pages that follow, information about each SmartState Center includes the date the center was approved, the institution(s) awarded, the state award amount that must be matched with an equal amount of non-state investment, the appointed endowed chair(s) as of November 2018, reported extramural research funding (federal and private awards) above the match, and a brief description of the research focus. Centers are grouped by industry cluster. For updated information on centers and program totals, contact the S.C. Commission on Higher Education or visit SmartStateSC.org.

- 51 SmartState® Program Centers Awarded
- 85 SmartState Endowed Chairs Created
- 75 SmartState Endowed Chairs Appointed
- 11 SmartState Endowed Chairs Remaining to be Appointed

	LEMSON I V E R S I T Y		NIVERSITY OF OUTH CAROLINA	MEDICAL	MUSC UNIVERSITY I CAROLINA
13	Awarded	18	Awarded	20	Awarded
16	Created	28	Created	41	Created
15	Appointed	25	Appointed	35	Appointed
1	Remaining	3	Remaining	7	Remaining



Advanced Materials & Nanotechnology

ADVANCED FIBER-BASED MATERIALS*

Award Date: 2006

State Award Amount: \$4 million

University: Clemson
Endowed Chair(s):
Dr. Marek Urban

J.E. Sirrine Foundation Endowed Chair in Advanced Fiber-Based Materials

Corporate Partner(s):

J.E. Sirrine Textile Foundation

External Funding Above Match:

\$14.8 million

Research Focus: To provide the vehicle for repositioning existing research and manufacturing resources to support new industrial and entrepreneurial opportunities based on advanced polymeric-based materials.

ENVIRONMENTAL NANOSCIENCE AND RISK*

Award Date: 2008

State Award Amount: \$3 million

University: USC Endowed Chair(s): Dr. Jamie Lead

External Funding Above Match:

\$4.7 million

Research Focus: Understand the fundamental properties of nanomaterials and nanomaterials-environment interaction and use these principles to understand and help reduce impacts of nanomaterials used as well as develop and innovate nanotechnological applications.

EXPERIMENTAL NANOSCALE PHYSICS*

Award Date: 2003

State Award Amount: \$4 million

University: USC Endowed Chair(s):

USC is recruiting one endowed chair.

External Funding Above Match:

\$6 millior

Research Focus: Perform basic and applied research of potential spintronic optoelectronic and nanoelectronic devices and/or materials for future applications in information processing, high-speed, high-density electronics, and bio, chemical and radiation sensing.

MULTIFUNCTIONAL MATERIALS & STRUCTURES (MFMS)*

Award Date: 2013

State Award Amount: \$2 million

University: USC
Endowed Chair(s):
Dr. Michel van Tooren

External Funding Above Match:

\$13.4 million

Research Focus: The development and supply of engineered materials for high technology industries such as aerospace by providing a foundation of research and development that will enable and enhance growth in the engineered materials field. Specific examples of research and development include:

Lightning strike and EMF management, structural integrity, energy storage, essential power for commercial aircraft, and multiphysics-based micro/nano mechanics of dielectric materials.

OPTICAL MATERIALS/PHOTONICS*

Award Date: 2004

State Award Amount: \$5 million

University: Clemson
Endowed Chair(s):
Dr. John Ballato

J. E. Sirrine Textile Foundation Endowed Chair

in Optical Fiber

Corporate Partner(s):

J.E. Sirrine Textile Foundation

External Funding Above Match:

\$30 million

Research Focus: Conduct optical and photonic materials research, particularly as relates to advanced optical fibers and fiber-based devices, and recruit and mentor graduate students with a focus on domestic scholars. Identify and foster the latest technologies and initiate partnerships with top national research universities and laboratories, aid South Carolina industry and economic development partners in the transfer of technology from Clemson to the public sector, and participate in the recruitment of optical technology firms to South Carolina.

POLYMER NANOCOMPOSITES*

Award Date: 2004

State Award Amount: \$3.5 million

University: USC

Endowed Chair(s):
Dr. Brian Benicewicz
Materials Science & Engineering

Corporate Partner(s):

Michelin North American, BASF, U.S. Navy, PBI Performance Products

External Funding Above Match:

\$18.5 million

Research Focus: Development of synthetic tools needed to precisely control the environment or interface between nanoparticles and polymer matrix applicable to optics, electronics, biological, medical, and structural material applications.

* Graduated Center

Once a center has reached a point of full operability, the SmartState Review Board has the authority to graduate SmartState centers. A center must meet the requirements in the following key areas to be considered graduated: non-state match; all draw downs; endowed chairs and key personnel; initiatory programmatic activities have been achieved; the most recent annual report cites demonstrable programmatic activity; and match certification. Once a center is graduated, the majority of fiscal and administrative oversight responsibilities are transferred to the center's lead fiscal institution. Certain accountability and reporting obligations are retained by the graduated center.

Automotive & Transportation

AUTOMOTIVE DESIGN AND DEVELOPMENT*

Award Date: 2004

State Award Amount: \$5 million

University: Clemson Endowed Chair(s):

Dr. Zoran Filipi

Timken Endowed Chair in Automotive Design & Development

Corporate Partner(s):

Hertz Corporation, Duke Energy

External Funding Above Match:

\$11 million

Research Focus: Focuses on the research and design of advanced powertrains for internal combustion engines and hybrid and electric vehicles, along with lightweight design and materials, functional integration and structural dynamics for vehicles.

AUTOMOTIVE MANUFACTURING*

Award Date: 2003

State Award Amount: \$5 million

University: Clemson

Endowed Chair(s):

Dr. Laine Mears BMW Endowed Chair in Automotive Manufacturing

Corporate Partner(s):

BMW

External Funding Above Match:

\$17.2 million

Research Focus: Seeks to reinvent the vehicle production system through developing processes inspired by car designs (transitioning from Design-for-Manufacturing thinking to Manufacturingfor-Design), and augmenting existing process capital through smarter modelbased control and applying energy fields to overcome material limitations. The guiding goals of this research are to improve productivity, reduce downtime, enhance quality, and more effectively integrate the human to the emerging digital information network.

AUTOMOTIVE SYSTEMS INTEGRATION*

Award Date: 2003

State Award Amount: \$5 million

University: Clemson

Endowed Chair(s):

Dr. Christiaan Paredis, Clemson

BMW Endowed Chair

in Automotive Systems Integration

Corporate Partner(s): BMW, Mazda,

GM and others

External Funding Above Match:

\$7.9 million

Research Focus: Automotive diagnostics and prognostics, sustainable mobility, concepts, methods and tools. Deriving a simple, flexible energy management control strategy for plug-in hybrid electric vehicles.

SUPPLY CHAIN OPTIMIZATION **AND LOGISTICS***

Award Date: 2006

State Award Amount: \$2 million

University: Clemson Endowed Chair(s):

Dr. Scott Mason Fluor Endowed Chair in Supply Chain Optimization & Logistics

Corporate Partner(s): Fluor

External Funding Above Match:

\$11.8 million

Research Focus: Interdisciplinary research addressing the multifaceted problems associated with supply chains. Deliver tangible supply chain optimization and logistics products and services through theoretical and applied research.

VEHICLE ELECTRONIC SYSTEMS INTEGRATION*

Award Date: 2004

State Award Amount: \$3 million

University: Clemson Endowed Chair(s):

> Dr. Venkat Krovi Michelin Endowed Chair in Vehicle Electronic

Systems Integration

Corporate Partner(s):

Michelin

External Funding Above Match:

\$4.7 million

Research Focus: Research to enable intravehicle and V2X automation, at subsystem, system, and system-of-systems levels, for automotive and vehicular applications.





ADVANCED TISSUE BIOFABRICATION

Award Date: 2008

State Award Amount: \$5 million **Universities:** MUSC, USC, Clemson

Endowed Chair(s):

Dr. Bruce Gao, Clemson Endowed Chair in Biofabrication Engineering

MUSC and USC are recruiting Endowed Chairs in *Biofabrication Biology*.

External Funding Above Match:

\$648.948

Research Focus: Develop innovative technologies and approaches that will enable repair, replacement, or restoration of diseased cells, tissues and organs.

BRAIN IMAGING

Award Date: 2003

State Award Amount: \$5 million

Universities: USC, MUSC

Endowed Chair(s):

Dr. Chris Rorden, USC

Dr. Joseph Helpern, MUSC

MUSC is recruiting one additional

endowed chair.

External Funding Above Match:

\$42.9 million

Research Focus: Creating a world-class brain imaging center. Initiated the first study using transcranial magnetic stimulation (TMS). Combined with functional MRI, TMS provides a short strong magnetic field useful for studying how the brain works. Specific studies include stroke-related brain injury and MRI physics techniques for clinical and neuroscience research.

CHILDHOOD NEUROTHERAPEUTICS

Award Date: 2006

State Award Amount: \$5 million

Universities: USC, MUSC

Endowed Chair(s):

Dr. Jeffery Twiss, USC

Child and Adolescent Neurochemistry

Dr. Manuel Casanova, USC Translational Clinical Research

MUSC is recruiting one endowed chair in *Neurodevelopmental Disorders*.

External Funding Above Match:

\$13 million

Research Focus: Prevention of brain damage in premature infants and curing infant brain diseases through cellular engineering. Also, working on cognitive behavioral tasks in transgenic mice to determine if therapeutics can improve functional development outcomes, which may someday help children with ADHD.

CLINICAL EFFECTIVENESS AND PATIENT SAFETY*

Award Date: 2006

State Award Amount: \$5 million

Universities: MUSC, USC

Endowed Chair(s):

Dr. John Schaefer, MUSC

Lewis Blackman Endowed Chair for Patient Simulation & Research for Health Sciences

South Carolina

Dr. Jihad Obeid, MUSC Biomedical Informatics

Dr. Cynthia Corbett, USC Endowed Chair in Chronic Care Management

External Funding Above Match:

\$12.9 million

Research Focus: Quality and safety of patient care, and improving the medical informatics aspects of data acquisition and the evaluation of health information technology on the quality and safety of clinical care processes and outcomes. The Center also focuses on developing South Carolina as a training center for physicians and other health professions using human simulators and sophisticated software-based training scenarios.

EFFECTIVENESS RESEARCH IN ORTHOPEDICS (CERotho)

Award Date: 2007

State Award Amount: \$5 million

University: USC
Endowed Chair(s):
Dr. John Brooks

Corporate Partner(s):

Smith & Nephew

External Funding Above Match:

\$17 million

Research Focus: Medical health needs in orthopaedic disorders, exercise and sports-related injury prevention, treatment, and rehabilitation. The Center investigates the biologics of tissue-engineered materials and implantable devices to find solutions to musculoskeletal maladies.





HEALTHCARE QUALITY*

Award Date: 2007

State Award Amount: \$5 million

Universities: USC, MUSC

Endowed Chair(s):

Dr. Les Lenert, MUSC *Medical Bioinformatics*

Dr. Xiaoming Li, USC Translational Clinical Research

Corporate Partner(s):

The Duke Endowment

External Funding Above Match:

\$22.9 million

Research Focus: Creating a unique and comprehensive clinical data store that collects data from providers, enhances data usability, and makes it available in an easily accessible form for participants to use for clinical improvement and research purposes.

HEALTH FACILITIES DESIGN AND TESTING

Award Date: 2007

State Award Amount: \$2 million

University: Clemson, MUSC

Endowed Chair(s):

Dr. Anjali Joseph, Clemson Architecture & Health Research

Dr. Kenneth Catchpole, MUSC Clinical Practice and Human Factors

External Funding Above Match:

\$5.4 million

Research Focus: The impact of the built environment on health and healthcare delivery and the creation of architectural settings that promote health, safety, and the wellbeing of all users.

INFLAMMATION AND FIBROSIS RESEARCH*

Award Date: 2010

State Award Amount: \$5 million

University: MUSC

Endowed Chair(s):

Dr. Carol Feghali-Bostwick Kitty Trask Holt Endowed Chair for Scleroderma Diseases

Dr. Betty Tsao Inflammation Research

External Funding Above Match:

\$33.9 million

Research Focus: Develop new therapies and education programs for inflammatory and fibrosing rheumatic diseases such as lupus, scleroderma, and rheumatoid arthritis.

MARINE GENOMICS*

Award Date: 2003

State Award Amount: \$4 million

Universities: MUSC, College of Charleston

Endowed Chair(s):

Dr. Gavin Naylor, MUSC Bioinformatics

Dr. Michael G. Janech, MUSC *Bioinformatics*

External Funding Above Match:

\$12 million

Research Focus: Monitoring and predicting

the impact of environmental changes on marine biosystems, which can, in turn, affect human health. Specific areas of study include environmental causation in wildlife, human disease and susceptibility, and mapping variability in genomes and populations; as well as research of shark and ray species.

MOLECULAR PROTEOMICS IN CARDIOVASCULAR DISEASE AND PREVENTION*

Award Date: 2006

State Award Amount: \$5 million

University: MUSC

Endowed Chair(s):

Dr. Sheldon E. Litwin Countess Alicia Spaulding Palozzi Chair in Cardiovascular Imaging

Dr. Thomas G. DiSalvo

Volpe SmartState Endowed Chair in Cardiovascular Biomarker Development for Diagnosis & Prevention

External Funding Above Match:

\$8.2 million

Research Focus: Translation advances in basic bench science to clinical bedside care to improve the health care of the citizens of South Carolina. Priorities include diagnostic techniques, therapeutic management strategies, relations of protein signatures to clinical outcomes for risk assessment, and treatment of disease manifestation.

NEUROSCIENCES

Award Date: 2003

State Award Amount: \$3 million

University: MUSC

Endowed Chair(s):

Dr. Christopher Cowan William E. Murray Endowed Chair in Neuroscience

MUSC is recruiting the *Josephine Tucker Morse Endowed Chair in Parkinson's Disease.*

External Funding Above Match:

\$19 million

Research Focus: Brain neuromodulatory systems and their roles in cognitive performance, drug abuse, sleep and affective disorders. Other areas of research are movement disorders such as Ataxia, Choro, Bradykinesia and multiple system atrophy.





PROSTATE CANCER DISPARITIES

Award Date: 2008

State Award Amount: \$3.6 million **University:** MUSC, USC, SCSU

Endowed Chair(s):

Dr. Chanita Hughes-Halbert, MUSC AT&T Distinguished Endowed Chair in Cancer Equity in Cancer Disparities

Dr. Marvella Ford, MUSC/SCSU *Cancer Disparities*

USC is recruiting an endowed chair in *Cancer Disparities*.

Corporate Partner(s): AT&T Foundation

External Funding Above Match:

\$48.6 million

Research Focus: Facilitate statewide partnerships in cancer prevention and control research, clinical trials, and training to significantly decrease disparities in prostate cancer incidence and mortality in South Carolina.

PROTEOMICS*

Award Date: 2003

State Award Amount: \$4 million

University: MUSC Endowed Chair(s): Dr. Richard Drake Dr. Anand S. Mehta

External Funding Above Match:

\$23.3 million

Research Focus: Develop and use high-end analytical technologies to understand the biologic profile of protein expression in health and disease. Developing enzyme-based analytical methods to effectively detect biomolecules in tissues and tissue microarray platforms.

REGENERATIVE MEDICINE*

Award Date: 2004

State Award Amount: \$5 million **Universities:** MUSC, USC, Clemson

Endowed Chair(s):

Dr. Martin Morad, USC

BlueCross BlueShield of SC Foundation Chair in

Cardiovascular Health

Dr. Stephen Duncan, MUSC Regenerative Medicine and Cell Biology

Dr. Jeremy Gilbert, Clemson Hansjörg Wyss Endowed Chair in Bioengineering

External Funding Above Match:

\$44.1 million

Research Focus: Regenerative medicine approach for cardiovascular applications and provide expertise in clinical trials, statistics and/or assay development. Application of regenerative medicine and tissue engineering approaches to orthopaedic and neural diseases. Regeneration of tissue and organs for repairing, replacing, and maintaining organ function.

RENAL DISEASE BIOMARKERS

Award Date: 2008

State Award Amount: \$5 million

University: MUSC
Endowed Chair(s):
Dr. Deepak Nihalani
Renal Biomarkers

MUSC is recruiting one endowed chair in *Translational Nephrology Research*.

External Funding Above Match:

\$8.2 million

Research Focus: Identifying biomarkers that identify or predict prognosis for acute kidney injury, diabetic neuropathy, lupus nephritis, and focal segmental alomerulosclerosis.

SENIORSMART®

Award Date: 2007

State Award Amount: \$5 million **Universities:** USC, Clemson

Endowed Chair(s):

Dr. Sue Levkoff, USC SmartHOME®

Dr. Julius Fridriksson, USC SmartBRAIN™

Clemson is recruiting one endowed chair in *SmartWHEELS™*.

External Funding Above Match:

\$14.7 million

Research Focus: Three areas of research include: *SmartBRAIN*™ (maintaining intellectual activity), *SmartWHEELS*™ (independent mobility outside the home) and *SmartHOME*® (independent mobility inside the home) to foster independent living among seniors.





STROKE*

Award Date: 2007

State Award Amount: \$5 million

Universities: MUSC, USC Endowed Chair(s):

Dr. Robert Adams, MUSC Stroke

Strok

Dr. Mark Chimowitz, MUSC

Countess Alicia Paolozzi Endowed Chair in Translational Neurology

Dr. Souvik Sen, USC Clinical Neurology

External Funding Above Match:

\$31.6 million

Research Focus: Enhancing stroke treatment, prevention, and recovery. This Center is developing new stroke-related therapeutics, drug discovery, and biotechnology, and is a leader in stroke telemedicine.

TECHNOLOGY CENTER TO ENHANCE HEALTHFUL LIFESTYLES*

Award Date: 2009

State Award Amount: \$3 million

Universities: USC, MUSC

Endowed Chair(s):

Dr. Frank Trieber, MUSC Technology Applications for Disease Prevention, Management, and Risk Reduction

Dr. Delia West, USC

Technology Application for Health Behavior

Change

External Funding Above Match:

\$18.5 million

Research Focus: Develop and test lifestyle interventions for improving health, preventing illness and managing chronic health problems caused by physical inactivity, poor diets, and other lifestyle behaviors.

TOBACCO-RELATED MALIGNANCY

Award Date: 2007

State Award Amount: \$5 million

University: MUSC Endowed Chair(s):

Dr. Nancy DeMore

BMW Chair in Cancer Research

MUSC is recruiting the *Burtschy Family*Distinguished Endowed Chair in Lung Cancer

Research.

Corporate Partner(s):

BMW

External Funding Above Match:

\$67.2 million

Research Focus: Devoted to discovering tobacco-related malignancy biomarkers via clinical trials with a specific focus on tobacco-related cancers. Additionally, the Center is evaluating the specificity and sensitivity of novel biomarkers by molecular epidemiologic techniques across the diverse populations of South Carolina.

TRANSLATIONAL BIOMEDICAL INFORMATICS

Award Date: 2013

State Award Amount: \$2 million

University: MUSC
Endowed Chair(s):
Dr. Stephane Meystre

Research Focus: The new Center will provide expertise in translational biomedical informatics essential for cutting-edge, innovative methodologies to link genetic/genomic data with vast amounts of clinical data. The contributions of the center to data sharing/analysis will decrease cost and increase efficiency in research and healthcare delivery and provide a robust IT platform for industry partnerships and new company formation.

External Funding Above Match:

\$539,697

VISION SCIENCE

Award Date: 2005

State Award Amount: \$4.5 million

Universities: MUSC Endowed Chair(s):

Dr. Baerbel Rohrer Chair in Gene and Pharmaceutical treatment

of Retinal Degenerative Diseases

MUSC is recruiting one endowed chair.

Corporate Partner(s):


Alcon Labs, Taligen, Alexion

Pharmaceuticals

External Funding Above Match:

\$27 million

Research Focus: New treatments for macular degeneration, development of new anti-glaucoma agents and innovations in cataract surgery. The Center also focuses on using advances in bioengineering and material sciences to improve the diagnosis, treatment, and prevention of eye diseases.





CATALYSIS FOR RENEWABLE FUELS*

Award Date: 2005

State Award Amount: \$3 million

University: USC

Endowed Chair(s):
Dr. John Regalbuto

External Funding Above Match:

\$13.6 million

Research Focus: Developing catalysts that allow production of alternative fuels from renewable sources, thereby reducing dependence on imported oil and carbon fuel. The Center focuses on synthesizing inorganic catalysts for converting biomass to biofuels and synthesizing electrocatalysts for solar fuels and fuel cells.

GENERAL ATOMICS CENTER FOR THE DEVELOPMENT OF TRANSLATIONAL NUCLEAR TECHNOLOGY

Award Date: 2009

University: USC

State Award Amount: \$3 million

Endowed Chair(s):
Dr. Theodore Besmann
Energy and Nuclear Security

Corporate Partner(s):General Atomics

External Funding Above Match:

\$45 million

Research Focus: The production of biofuels and coal to liquid fuels using nuclear process heat for more efficient production and the reduction of wastes associated with recycling of used fuel, seeking more long term strategies to manage used fuel, recovery of energy value in used fuel, and eliminating concerns over proliferation associated with recycling used fuel.

NUCLEAR SCIENCE AND ENERGY

Award Date: 2008

University: USC

State Award Amount: \$3 million

Endowed Chair(s):
Dr. Dan Gabriel Cacuci
Nuclear Power and Advanced Materials

Corporate Partner(s):

Duke Energy, Progress Energy, SCANA, Westinghouse

External Funding Above Match:

\$7.3 million

Research Focus: Performance, efficiency, and maintenance issues at existing and future nuclear power plants using expertise modeling and simulation related to nuclear fuels and materials.

SMART GRID TECHNOLOGY

Award Date: 2013

State Award Amount: \$5 million

University: Clemson
Endowed Chair(s):
Dr. Johan Enslin

Duke Energy Smart Grid Technology Chair

Corporate Partner(s):

Duke Energy

External Funding Above Match:

\$6.9 million

Research Focus: Develop technology to better plan and operate electric power systems.

SOLID OXIDE FUEL CELLS*

Award Date: 2006

State Award Amount: \$3 million

University: USC

Endowed Chair(s):

Dr. Kevin Huang, USC

Solid Oxide Fuel Cells

External Funding Above Match:

\$60.1 million

Research Focus: Develop solid oxide fuel cells for use in large, high-power systems such as industrial sites and electricity generating stations as well as for mobile power for computers, cell phones, and other electronics.

STRATEGIC APPROACHES TO THE GENERATION OF ELECTRICITY (SAGE)*

Award Date: 2007

State Award Amount: \$5 million

University: USC
Endowed Chair(s):
Dr. Jochen Lauterbach

External Funding Above Match:

\$13 million

Research Focus: Developing, improving, and advancing technologies to enhance the environmental performance of electricity production. Other work focuses on converting CO2 to chemicals, fuel cell and hydrogen storage-related research, and chemical production from coal to biomass.



Information Science

CYBERINSTITUTE

Award Date: 2008

State Award Amount: \$2 million

University: Clemson Endowed Chair(s): Dr. Sally McKee

C. Tycho Howle Endowed Chair in Collaborative Computing Environments.

Corporate Partner(s):

Omnibond Systems, LLC

External Funding Above Match: \$7.6 million

Research Focus: Connecting research and scholarship, particularly in interdisciplinary aspects of high-performance computing, networking, and data storage; the security of information systems and networks; humancomputer interactions; interpretation; and visualization to the commercial sector via strategic industrial partnerships. Conduct research in conjunction with the Clemson University Cyber-Institute.

DATA ANALYSIS, SIMULATION, IMAGING, AND VISUALIZATION

Award Date: 2010

University: USC

State Award Amount: \$2 million

Endowed Chair(s): Dr. Wolfgang Dahmen Williams-Hedberg-Hedberg Chair of Mathematics

External Funding Above Match:

\$3.1 million

Research Focus: Develop technology for transforming data into knowledge concentrating on inline data processing, multi-sensor data acquisition, tissue modeling, atomic scale modeling, and bioimaging

INNOVATION AND COMMERCIALIZATION

Award Date: 2004

State Award Amount: \$5 million

University: USC Endowed Chair(s): Dr. Laura B. Cardinal Discovery and Innovation

Corporate Partner(s):

Fluor Foundation and Savanah River **Nuclear Solutions LLC**

External Funding Above Match:

\$19.8 million

Research Focus: The innovation, commercialization, and new venture development of research in the SmartState Centers, leading to technology commercialization and transfer activities in collaboration with business organizations and public sector stakeholders.

OPTOELECTRONICS*

Award Date: 2008

State Award Amount: \$2 million

University: Clemson Endowed Chair(s): Dr. Eric Johnson

PalmettoNet Endowed Chair in Optoelectronics

Corporate Partner(s):

Advanced Photonic Crystal, Tetramer Technologies

External Funding Above Match:

\$12 million

Research Focus: Improving devices, systems, and protocols used in high-speed optical communications networks.

SUSTAINABLE DEVELOPMENT*

Award Date: 2010

State Award Amount: \$4 million

University: Clemson

Endowed Chair(s):

Dr. Mark Johnson

Thomas F. Hash '69 Endowed Chair in Sustainable Development.

External Funding Above Match:

\$6.5 million

Research Focus: Developing new technologies to support real-time monitoring and management of natural and built environments through the Intelligent River® Project. The Center has created wireless sensor networks that can reliably monitor and transmit environmental data in near real time.

TOURISM AND ECONOMIC DEVELOPMENT*

Award Date: 2005

State Award Amount: \$2 million

University: USC Endowed Chair(s):

Dr. Simon Hudson Corporate Partner(s):

Rawle Murdy

US Travel Association (USTA)

External Funding Above Match:

\$568 107

Research Focus: Tourism is a \$17 billion industry in South Carolina. The Center conducts cutting-edge tourism and hospitality research initiatives that will improve South Carolina's competitiveness as a tourism destination.

URBAN ECOLOGY AND RESTORATION*

Award Date: 2006

State Award Amount: \$2 million

University: Clemson

Endowed Chair(s):

Dr. Robert F. Baldwin Margaret H. Lloyd SmartState Chair in Urban Ecology

External Funding Above Match:

\$7.9 million

Research Focus: Generating scholarship by building collaborations in applied ecology and environmental science, habitat ecology and restoration, wetland and watershed management; conservation biology; private-public networks for conservation; payments for ecosystem services; urban ecology; environmental education; and by developing careers of young scientists and educators.





CANCER DRUG DISCOVERY*

Award Date: 2005

State Award Amount: \$5 million

Universities: MUSC, USC

Endowed Chair(s):

Dr. John LeMasters, MUSC GlaxoSmithKline Distinguished Endowed Chair

Dr. Patrick Woster, MUSC Medicinal Chemistry

Dr. Mark Hamann, MUSC
Charles & Carol Cooper Chair in Pharmacy

Dr. Mitzi Nagarkatti, USC Structural Biology and Pharmacy

Corporate Partner(s):

GlaxoSmithKline

External Funding Above Match:

\$21 million

Research Focus: Advanced biomedical screening technologies to identify disease mechanisms and targets, and also screening drug candidates. Structural biology for target analysis, chemical biology for designing drug candidates, and advanced biomedical screening technologies.

CANCER STEM CELL BIOLOGY AND THERAPY*

Award Date: 2008

State Award Amount: \$5 million **Universities:** MUSC, Clemson

Endowed Chair(s):

Dr. Zihai Li, MUSC

Abney Endowed Chair Remembering Sally

Abney Rose

Dr. Xue Zhong Yu, MUSC Biomedical Engineering

External Funding Above Match:

\$29 million

Research Focus: Developing new technologies for isolating, growing, and manipulating cancer stem cells. This will enable the Center to find ways to use adult stem cells from bone marrow or organs to treat cancer.

GASTROINTESTINAL CANCER DIAGNOSTICS

Award Date: 2005

State Award Amount: \$5 million

University: MUSC

Endowed Chair(s):

Dr. Carolyn Britten

Charles Westerfield Coker Distingu

Charles Westerfield Coker Distinguished Chair in Gastrointestinal Malignancy

Dr. Gustavo Leone, MUSC Grace DeWolff Endowed Chair in Medical Oncology

Corporate Partner(s):

Roche Carolina, Bank of America

External Funding Above Match:

\$18 million

Research Focus: Clinical and translational gastrointestinal oncology and biomarker development and gastrointestinal (GI) malignancies. Bringing state-of-the-art translational medicine to all GI cancer patients in South Carolina, thereby decreasing the overall impact of cancer mortality and morbidity and closing disparity gaps throughout the state.

LIPIDOMICS, PATHOBIOLOGY AND THERAPY*

Award Date: 2009

State Award Amount: \$5 million

University: MUSC Endowed Chair(s): Dr. J. Alan Diehl

Lipidomics & Pathobiology

Dr. Besim Ogretmen
Lipidomics Drug Discovery

External Funding Above Match:

\$38 million

Research Focus: Develop models for translational research and study of lipidomics and their pathobiology with an emphasis on cancer and inflammation.

MEDICATION SAFETY AND EFFICACY

Award Date: 2008

State Award Amount: \$2 million

Universities: MUSC, USC

Endowed Chair(s):

Dr. Charles Bennett, USC Frank P. and Josie M. Fletcher Professor of Pharmacy

External Funding Above Match:

\$6.7 million

Research Focus: Increasing drug safety and effectiveness, as well as decreasing medication errors by identifying the incidence and significance of adverse drug events.

TRANSLATIONAL CANCER THERAPEUTICS*

Award Date: 2004

State Award Amount: \$5 million

Universities: MUSC, USC

Endowed Chair(s):

Dr. Kenneth Tew, MUSC John C. West Endowed Chair in Cancer Research

Dr. Igor Roninson, USC Drug Efficacy

External Funding Above Match:

\$40 million

Research Focus: Development of new approaches in cancer treatment, including the discovery and development of new drugs. Research also focuses on utilizing mouse models predisposed to cancer to study the impact of gene misregulation and therapeutic agents on tumor development, and the identification and inhibition of new cancer drug targets.

The sky is not the limit



USC's McNAIR Center gains altitude in research and education Chris Horn

If the McNAIR Center for Aerospace Innovation and Research magically sprouted wings, it would probably be some kind of cool experimental aircraft with an advanced composite fiber fuselage. That wouldn't be a stretch of the imagination considering the roster of aerospace talent the center has attracted and the collective energy of 50 undergraduate and graduate students who rub elbows there every day. But rewind the tape four years to when the center had only a couple of offices, four people and no research equipment. Imagining the McNAIR Center back then as anything more than a paper airplane would have required a real leap of faith.

Taking flight

"When I arrived, basically, there was nothing," says Michel van Tooren, who started out as the McNAIR Center's second research professor and was recently appointed the center's director. "But when I was teaching at Delft University of Technology, I had been awarded as the second most entrepreneurial professor in the Netherlands in 2010. I know how a startup works; I know how to write a business plan and raise money. And here, at least, there was a startup donation to get things moving."

That \$5 million pledge from Carolina alumna and benefactor Darla Moore laid the groundwork for the center, complemented by an additional \$5 million pledge from Anita Zucker, chairwoman and CEO of the Intertech Group. USC alumna Marva Smalls, an executive vice president at Viacom and Nickelodeon, gave \$1 million to endow scholarships for minority students from the Pee Dee region majoring in computer science and engineering at USC.

Zafer Gurdal, an aerospace engineer and the center's first director, van Tooren and business manager Martin Keaney together got the center ready for takeoff. After acquiring a fiber-placement machine, a set of robots and an induction heater and outfitting a large research lab in the S.C. Research Authority building on Catawba Street, the center began to take flight.



"By the beginning of 2016, people started seeing what we were going to do in terms of a research agenda," van Tooren says. "That got Boeing interested, and we signed our first big contract (\$5 million) with them to look at manufacturing technology, especially fiber placement, induction welding and nondestructive evaluation."

One of van Tooren's ongoing goals — and one that's close to being realized — is the creation of an undergraduate degree program in aerospace engineering within the College of Engineering and Computing. A small master's program is already in place, and a full bachelor's degree program will create a pipeline of students to make the center's activities sustainable.

"We now have a specialized section of the introduction to engineering that emphasizes aerospace engineering, and there are 50 freshmen who indicated during enrollment that this is their goal — to become aerospace engineers," van Tooren says. "This could be our first cohort of aerospace engineering majors."

Through the McNAIR fellowship program, an initiative of Ramy Harik, an assistant professor in the McNAIR Center who joined in 2014, undergraduates commit at least five hours per week to research activities at the center, working under the supervision of graduate students, faculty and lab staff. Those who complete three semesters get a certificate, internship experiences and can then apply for summer jobs at the center.

High-flying deals

Boeing's big contract with the McNAIR Center grabbed attention, but the center has been inking deals with many other aerospace partners, as well, including okker, NASA, GE Renewable, Carbon Conversions and Ingersoll, which provided the carbon fiber-placement equipment. Many of Ingersoll's customers rent the McNair Center's machine and harness the center's technical expertise or contract with the center to build sample parts for testing. The McNAIR Center will soon lease more space in the SCRA building to welcome the Center for Predictive Maintenance, a long-term research project led by mechanical engineering professor Abdel Bayoumi that has focused on Army helicopter maintenance.

"We've focused in the beginning on composites manufacturing because that's what Boeing is using at their Charleston plant, but we need to give our students some exposure to aircraft design, as well," van Tooren says. "We need to go way beyond materials design."

To that end, the center director envisions building a wind tunnel in the laboratory and a flight cage for experimenting with drones. He also points to the broadening of disciplines from which new aerospace faculty are coming — not just mechanical engineering but also electrical, chemical and integrated information technology.

"The state of South Carolina has more than 400 aerospace-related companies that cover the whole supply chain," he says. "It makes a lot of sense to widen the range of engineers we train here. There are so many companies and so many potential opportunities for our graduates."

The future looks bright for the aerospace industry in South Carolina — and for the McNAIR Center's plans to grow with it, van Tooren says. He references a recent economic impact study released by the South Carolina Council on Competitiveness that shows the impact of aerospace on South Carolina's economy has grown to 1 billion, an increase of 2 billion since 2014.

"This year's research shows a clear indication that the industry is diversifying and trending towards sustainable growth. We see that the majority of firms continue to be small businesses with fewer than five employees," says Joey Von Nessen, a research economist at the Darla Moore School of Business. "We also see growth, not just in aircraft manufacturing, but also in engine manufacturing, instruments manufacturing and other types of firms."

All of that translates into more opportunity for the McNAIR Center to fly higher and farther, van Tooren says. "We've still got a long way to go," he says, "but we're growing every month."



SMARTSTATE® PROGRAM

Endowed Chairs

The role of SmartState® Program Endowed Chairs is to serve as catalyst for the state's knowledge economy. Seventy-five chairs of 85 approved chairs have been filled at Clemson University, the Medical University of South Carolina, and the University of South Carolina across 51 SmartState Centers. The SmartState® Program welcomed three new endowed chairs this year: Dr. Sally McKee, Dr. Michael G. Janech, and Dr. Mark Johnson.



ROBERT ADAMS Stroke MUSC



ROBERT F. BALDWINUrban Ecology and Restoration
Clemson



JOHN BALLATO
Optical Materials/Photonics
Clemson



BRIAN BENICEWICZ Polymer Nanocomposites USC



CHARLES BENNETTMedication Safety and Efficacy
USC



THEODORE BESMANN
General Atomics



CAROLYN BRITTEN Gastrointestinal Cancer Diagnostics MUSC



JOHN BROOKS Effectiveness Research in Orthopedics USC



DAN GABRIEL CACUCI Nuclear Science and Energy USC



LAURA B. CARDINAL Innovation and Commercialization USC



MANUEL CASANOVAChildhood Neurotherapeutics
USC



KENNETH CATCHPOLEHealth Facilities Design and Testing
MUSC



MARK CHIMOWITZ Stroke MUSC



CYNTHIA CORBETT CEPS USC



CHRISTOPHER COWAN
Neurosciences
MUSC



WOLFGANG DAHMEN Data Analysis Simulation Imaging and Visualization USC



NANCY DEMORE

Tobacco-related Malignancies

MUSC



J. ALAN DIEHL Lipidomics Pathobiology and Therapy MUSC



THOMAS DISALVO
Molecular Proteomics in
Cardiovascular Disease and
Prevention
MUSC



RICHARD DRAKE Proteomics MUSC



STEPHEN A. DUNCAN Regenerative Medicine MUSC



JOHAN ENSLINSmart Grid Technology
Clemson



CAROL FEGHALI-BOSTWICK Inflammation & Fibrosis Research MUSC



ZORAN FILIPIAutomotive Design and
Development
Clemson



MARVELLA FORDProstate Cancer Disparities
MUSC/SCSU



JULIUS FRIDRIKSSON SeniorSMART® USC



BRUCE GAOAdvanced Tissue Biofabrication
Clemson



JEREMY GILBERT Regenerative Medicine Clemson



MARK HAMANN Cancer Drug Discovery MUSC



JOSEPH HELPERN Brain Imaging MUSC



KEVIN HUANG Solid Oxide Fuel Cells USC



SIMON HUDSON Tourism and Economic Development USC



CHANITA HUGHES- HALPERTProstate Cancer Disparities

MUSC



MICHAEL JANECH
Marine Genomics
MUSC



ERIC JOHNSONOptoelectronics
Clemson



MARK JOHNSONSustainable Development
Clemson



ANJALI JOSEPHHealth Facilities Design and Testing
Clemson



VENKAT KROVI Vehicle Electronic Systems Integration Clemson



JOCHEN LAUTERBACH Strategic Approaches to the Generation of Electricity (SAGE) USC



JAMIE LEAD
Environmental Nanoscience
and Risk
USC



JOHN LEMASTERSCancer Drug Discovery
MUSC



GUSTAVO LEONEGastrointestinal Diagnostics
MUSC




LES LENERT Healthcare Quality MUSC



SUE LEVKOFF SeniorSMART* USC



XIAOMING LI Healthcare Quality USC



ZIHAI LICancer Stem Cell Biology and Therapy
MUSC



SHELDON E. LITWIN Molecular Proteomics in Cardiovascular Disease and Prevention MUSC



HESHING LIU Brain Imaging MUSC



SCOTT MASON Supply Chain Optimization and Logistics Clemson



SALLY MCKEECyberinstitute
Clemson



LAINE MEARSAutomotive Manufacturing
Clemson



ANAND S. MEHTA Proteomics MUSC



STEPHANE MEYSTRE Translational Biomedical Informatics MUSC



MARTIN MORAD Regenerative Medicine USC



MITZI NAGARKATTI Cancer Drug Discovery USC



GAVIN NAYLOR *Marine Genomics*MUSC



DEEPAK NIHALANI Renal Disease Biomarkers MUSC



JIHAD OBEID Clinical Effectiveness and Patient Safety MUSC



BESIM OGRETMENLipidomics Pathobiology and Therapy
MUSC



CHRISTIAAN PAREDISAutomotive Systems Integration
Clemson



JOHN REGALBUTO Catalysis for Renewable Fuels USC



BAERBEL ROHRER Vision Science MUSC



IGOR RONINSONTranslational Cancer Therapeutics
USC



CHRIS RORDENBrain Imaging
USC



JOHN SCHAEFER Clinical Effectiveness and Patient Safety MUSC



SOUVIK SEN Stroke USC



KENNETH TEWTranslational Cancer Therapeutics
MUSC



FRANK TRIEBER
Technology Center to Enhance
Healthful Lifestyles
MUSC



BETTY TSAOInflammation and Fibrosis
Research
MUSC



JEFFERY TWISSChildhood Neurotherapeutics
USC



MAREK URBAN Advanced Fiber Materials Clemson




MICHAEL VAN TOOREN
Multifunctional Materials &
Structures
USC



DELIA WESTTechnology Center to Enhance
Healthful Lifestyles
USC



PATRICK WOSTER
Cancer Drug Discovery
MUSC



XUE ZHONG YU

Cancer Stem Cell Biology and
Therapy
MUSC

Cancer biologist leads team in unraveling cellular activity

Research details functional breakdowns that lead to cancer, point to therapeutic possibilities Leslie Cantu | cantul@musc.edu



Generations of high school students have memorized the basic phases of cell division — and more than likely forgotten them by the time summer rolls around. But as class after class has labored over its four distinct phases — G1, S, G2 and mitosis — researchers in the lab have been painstakingly adding to the body of knowledge of precisely how each phase is accomplished. By revealing what occurs when everything goes as planned, they also have shown how things can go awry.

J. Alan Diehl, Ph.D., the SmartState endowed chair in lipidomics, pathobiology and therapy and associate director of basic sciences at the Hollings Cancer Center, has devoted his career to studying how a breakdown in normal pathways gives rise to cancer. The National Institutes of Health recently awarded Diehl an additional \$1.6 million to continue the work he began in 2000. The grant will enable him to continue this work through 2023.

Research, he said, starts with a basic question: "How does this work?"



A National Institutes of Health grant will enable Dr. Alan Diehl to continue studying the inner workings of cell division. When cell division goes wrong, it can lead to cancer. Photo by Sarah Pack

"What I tell students and postdocs is, if you ask a good, relevant question and you develop experiments that answer that question, you will see opportunities to translate this to treatments," he said.

However, you can't necessarily predict where those treatment opportunities will arise, he said.

"Sometimes, it's not the enzyme itself; it's something that it does. It triggers a vulnerability in the tumor cell that you would have had no idea was there unless you spent some time doing what appears to be very esoteric research, answering esoteric questions," he said. The essence of his work is figuring out what controls the expression of particular proteins in a normal cell and what happens to those proteins in a cancer cell. His lab has found that these proteins take on new functions though their inherent actions haven't changed.

"It's doing something that it shouldn't do, and it's doing that because it's in the wrong place at the wrong time and not turned off when it should be," he said. Proteins called cyclins – so named because they're supposed to cycle through synthesis and degradation — function within the nucleus of a cell. Cyclin D1 helps regulate the G1 phase of cell division. When its work is done, it's supposed to be ejected into the cytoplasm and destroyed. If it instead remains in the nucleus, it's "turned on" indefinitely.

Cyclin D1 is well studied because it's long been known to be dysregulated in multiple cancers, including metastatic breast cancer, head and neck cancers, endometrial and uterine cancers and mantle cell lymphoma. In the past few years, the FDA has approved three new drugs that target the enzymes that partner with cyclin D1. The drugs are approved for certain types of metastatic breast cancer.

Less well studied are cyclins D2 and D3. Diehl's lab is looking at cyclin D3, and next year, he expects to publish a paper about its role. Cyclin D3 is mutated in patients with Burkitt lymphoma, but there's no published data yet about whether the mutation is a result of the cancer or is causing the cancer. The only clue is that cyclin D1 is cancer causing when it has a similar mutation. Researchers are studying how the accumulation and loss of cyclin D3 is regulated – how it turns on and off and why it's mutated more often in Burkitt lymphoma than in mantle cell lymphoma.

Once researchers understand the regulators of cyclins D2 and D3, they can start building models of diseases, and from there develop better treatments. Scientists have learned so much just by doing good, fundamental cell biology and biochemistry research, Diehl said.

While he can't predict what the next cancer-fighting drug will be, he said he can ask questions and recognize opportunities. "You can't always predict where those are going to be without doing the experiments and learning," he said.

SMARTSTATEProgram Contacts

South Carolina Commission on Higher Education

Jeff Schilz

Interim Executive Director 803.737.2155 jschilz@che.sc.gov

Dr. John Lane

Director of Academic Affairs 803.737.0141 jlane@che.sc.gov

Dr. Argentini Anderson

Assistant Director of Academic Affairs 803.737.2276 aanderson@che.sc.gov

Tanya Rogers

Program Coordinator Academic Affairs 803.737.2224 trogers@che.sc.gov

University Research

Clemson University

Dr. Tanju KaranfilVice President for Research tkaranf@clemson.edu

Chris Gesswein

Interim Executive Director Clemson University Research Foundation agesswe@clemson.edu

Medical University of South Carolina (MUSC)

Dr. Kathleen T. Brady *Vice President for Research*bradyk@musc.edu

Michael Rusnak

Executive Director, Foundation for University Research rusnak@musc.edu

University of South Carolina

Dr. Prakash Nagarkatti Vice President for Research Carolina Distinguished Professor

prakash@mailbox.sc.edu

William Kirkland

Director
Office of Economic Development
kirkla@mailbox.sc.edu

University Media Relations

Mark David Land

Vice President for University Relations 864.656.4233 mdland@clemson.edu

Heather M. Woolwine, MA

Media Relations Director 843.792.7669 woolwinh@musc.edu

Wes Hickman

University of South Carolina Director, News & Internal Communications 803.777.3478 whickman@mailbox.sc.edu

The SmartState® Program annual report is prepared annually for the South Carolina General Assembly and the South Carolina Budget and Control Board by the SmartState Review Board and the South Carolina Commission on Higher Education in accordance with S.C. Code of Laws §2-75-10.

In accordance with S.C. Code of Laws §1-11-425, the following information is provided: Number of reports printed: 350. Cost per report: \$5.492. Total printing cost: \$1,922.40



SOUTH CAROLINA CENTERS OF ECONOMIC EXCELLENCE

FINANCIAL AND COMPLIANCE REPORT

JUNE 30, 2018



SOUTH CAROLINA CENTERS OF ECONOMIC EXCELLENCE

YEAR ENDED JUNE 30, 2018

TABLE OF CONTENTS

	<u>Page</u>
Review Board	
Transmittal Letter	2- 9
SECTION I - FINANCIAL STATEMENTS	
INDEPENDENT AUDITOR'S REPORT ON FINANCIAL STATEMENT	10 and 11
Statement of program revenues, expenditures and changes in fund Balances – consolidated summary	12 and 13
Notes to financial statement	14 - 18
SECTION II – SUPPLEMENTARY INFORMATION	
Schedule of program revenues, expenditures and changes in fund Balances – Clemson University	40. 25
Schedule of program revenues, expenditures and changes in fund	19 - 25
Balances – Medical University of South Carolina	26 - 36
Schedule of program revenues, expenditures and changes in fund	
Balances - University of South Carolina	37 - 46

SOUTH CAROLINA CENTERS OF ECONOMIC EXCELLENCE

REVIEW BOARD JUNE 30, 2018

NAME	POSITION	<u>APPOINTMENT</u>
Jason Premo	Chair	Chair, Senate Finance Committee
Karoly Kerekes	Vice-Chair	President Pro Tempore of the Senate
Lisa Main	Secretary	Speaker of the House
Robert W. Pearce, Jr.	Member	Speaker of the House
Charles W. Garnett	Member	Governor
Melvin C. Williams	Member	Governor
Roberta Bankhead Wood	Member	Chair, House Ways and Means Committee
James P. Clements	Ex-Officio	President, Clemson Univ.
David J. Cole	Ex-Officio	President, Medical Univ. of S.C.
Harris Pastides	Ex-Officio	President, Univ. of S. C.



SmartState® Program Transmittal Letter Period: Fiscal Year 2017-2018

This transmittal letter provides an overview of the SmartState program and data covering the fiscal year ended June 30, 2018. This discussion and analysis should be read in conjunction with the financial statement and accompanying notes. The financial statements have been audited by an independent auditor (Mauldin & Jenskins) in accordance with S.C. Code of Laws, as amended, Section 2-75-10.

Overview of the SmartState Program

In 2002, the South Carolina General Assembly passed the Research Centers of Economic Excellence (RCEE) Act. The legislation originally required appropriation of \$200 million through 2010¹ from the South Carolina Education Lottery to establish unique Centers of Economic Excellence at South Carolina's three senior research institutions: Clemson University, University of South Carolina (USC), and Medical University of South Carolina (MUSC). Each Center of Economic Excellence (Center) specializes in unique, knowledge-based economy research (in fields such as engineering, nanotechnology, biomedical science, and energy science) that promotes and creates enhanced economic opportunities for the state. In 2008, the General Assembly amended the RCEE Act to replace the \$200 million funding cap and the 2010 sunset date with a statutory guarantee of \$30 million in annual funding so long as (a) Lottery-supported scholarships have been fully funded, and (b) the SmartState Review Board has, by the end of the most previous fiscal year, awarded a minimum of 80% of overall appropriations since 2003.

The RCEE Act also created the SmartState Review Board, which provides program oversight. The Review Board is composed of 11 members: three appointed by the

¹ The General Assembly appropriated \$30 million per year in the state budget for fiscal years 2003 through 2008. The General Assembly has appropriated no new funds for fiscal years 2009 through 2017.

Governor; three by the President Pro Tempore of the Senate; three by the Speaker of the House of Representatives; one by the Chair of the Senate Finance Committee; and one by the Chair of the House Ways & Means Committee. Membership terms are three years, and individuals may serve three total terms. Presidents of South Carolina's three research universities serve as ex-officio, non-voting members of the Review Board. Staff and operational support for the SmartState Program are provided by CHE.

The SmartState Review Board held its first meeting on October 17, 2002, at which it approved formal *Bylaws*. On December 5, 2002, the Review Board approved Program *Guidelines* and *Requests for Proposals Guidelines for 2002-2003*, which established a competitive, annual process whereby Centers of Economic Excellence are proposed by the research institutions and approved by the Review Board. The three-tier review process includes two rigorous scientific evaluations (a technical review and an onsite panel review), followed by the Review Board's analysis of the review findings and a formal vote on individual proposals. In 2008, the General Assembly amended the RCEE Act by encoding the technical and scientific review process for proposals.

Once a new Center is approved, an institution has 18 months in which to solicit non-state (private, federal, or municipal) investors to pledge dollar-for-dollar matching of a Center's total state award (between \$2 million to \$5 million). In February 2007, the SmartState Review Board approved a policy whereby an institution may apply for up to two six-month extensions beyond the 18-month pledge verification deadline. All matching pledges must be realized within 78 months of a Center's approval date. In February 2009, the SmartState Review Board approved a policy whereby an institution may apply for as many as two six-month extensions beyond the 78-month drawdown deadline.

State funds may only be drawn against perfected (eligible and received) non-state pledges. The majority of funds (all of the state funds plus no less than 30% of the non-state match) is placed in endowment, which may be used to pay the salaries or salary supplements of the world-class scientists (endowed chairs) specially recruited to lead each Center, as well as to pay for the purchase of specialized equipment, laboratory construction, other faculty, and research assistants. In 2008, the General Assembly amended the RCEE Act by codifying the use of a certain portion (determined by the

SmartState Review Board) of non-state matching funds "to pay for initial operating costs" of Centers (S.C. 2-75-100).

On December 12, 2006, the SmartState Review Board convened a Cost Share Work Group. Representatives from all three research institutions, the Office of the State Treasurer, and CHE gathered to discuss accounting standards related to the RCEE Act. On February 26, 2007, the Review Board approved a Cost Share Accounting Policy which contains specific guidelines for claiming and valuing in-kind matches. In 2008, the General Assembly amended the RCEE Act to encode the use of cash equivalent and in-kind donations as valid non-state matches for the SmartState Program.

In 2010, the General Assembly amended the RCEE act to create a new type of SmartState award to be made in concert with the South Carolina Department of Commerce. Onequarter of the unallocated Centers of Excellence Matching Endowment funds were dedicated for funding such "SmartState Commerce Awards." SmartState Commerce Awards may not individually exceed \$2 million and do not require the dollar-for-dollar, non-state match of standard SmartState awards. In place of the matching requirement, the Secretary of Commerce is required to certify that a "significant capital investment" has been made in the related research field of the proposed SmartState Commerce Award professorial endowment. These revisions became effective January 1, 2011. The SmartState Review Board issued an RFP for awards in FY 2011. At the request of the Department of Commerce, the awards for this component of the SmartState Program have not been made. However, during the 2015-2016 legislative session, the SC General Assembly approved Proviso 117.139², which states that the SmartState Endowed Chairs Program funds earmarked for Commerce Awards shall be transferred by the Commission on Higher Education to the Department of Commerce's Applied Research Centers by August 1, 2016. The program fund amount of \$2.8 million was transferred to the Department of Commerce on July 25, 2016.

Over time, each research institution has developed concentrated SmartState focus areas. Clemson University's core strengths lie in the area of automotive and transportation technology, advanced materials and biotechnology/biomedical sciences. USC's Centers

[,]

² Part 1B Proviso 117.139, FY 2015-16, states: The Endowed Chairs Program funds that have been set aside for "Commerce Awards" shall be transferred by the Commission on Higher Education to the Department of Commerce's Applied Research Centers by August 1, 2016.

generally fall within three clusters: future fuels, biomedical sciences, and nanotechnology. MUSC's strengths lie in the areas of neuroscience, cancer research, vascular disease, and health care quality and finance.

One hallmark of the SmartState Program is an almost unprecedented scientific collaboration at the academic level. More than one-third of the Centers are partnerships between and among state public institutions, including three four-year comprehensive teaching universities. Dr. John Schaefer, SmartState Endowed Chair at MUSC's Clinical Effectiveness and Patient Safety Center has noted that such academic collaboration rarely exists—not even at Harvard or Yale. The lure of bonded research partnerships serves as an enticing recruiting tool to the renowned scientists required to lead each Center.

2017-18 SmartState Summary Information

At the end of FY 2017-18, the program consists of 51 Centers with 85 approved SmartState Endowed Chairs of which 74 have been appointed. As envisioned by the General Assembly, the SmartState Program has become a successful boost to the state's knowledge-based economy. Of the \$197.6 million³ in SmartState awards granted by the Board through the end of FY 2017-18, \$197.6 million in matching pledges have been committed by non-state sources. Of the committed pledges through FY 2017-18, \$197.6 million have been perfected and drawn down.

The table found on the following pages provides summary information on the Centers from FY 2002-03 through FY 2017-18.

5

³ To date, the SmartState Review Board has obligated \$17.6 million in accrued program interest for the awarding of additional proposals, as is permitted by statute. To date, the Review Board has used all of the \$17.6 million in accrued interest to fund proposals in the 2008-2009, 2009-2010 and 2012-2013 award cycles.



Summary of Approved SmartState Program Centers of Economic Excellence by Fiscal (Funding) Year (2002-03 – 2017-18)

Centers of Economic E	xcellence by Fiscal (Funding) Ye Funding Year 2002-2003	ur (2002 00	2017 10)
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount
Clemson	Automotive Systems Integration	1	\$5 million
Clemson	Automotive Manufacturing	1	\$5 million
USC	Nanostructures	1	\$4 million
USC/MUSC	Brain Imaging	31	\$5 million
MUSC	Proteomics	2	\$4 million
MUSC	Neuroscience	2^2	\$3 million
MUSC/USC/CoC	Marine Genomics	24	\$4 million
Total Awarded in 2002-2003	3	12	\$30 million
	Funding Year 2003-2004		
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount
Clemson	Automotive Design & Development	1	\$5 million
Clemson	Electronic Systems Integration	1	\$3 million
Clemson	Photonic Materials	1	\$5 million
USC	Polymer Nanocomposites	1	\$3.5 million
USC	Innovation and Commercialization	1 ⁴	\$2.5 million
MUSC/Clemson/USC	Regenerative Medicine	3	\$5 million
MUSC/USC	Translational Cancer Therapeutics	2	\$5 million
Total Awarded in 2003-2004		10	\$29 million
	Funding Year 2004-2005		
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount
Clemson	Restoration [WITHDRAWN]	_	[\$3 million]
Clemson	Electron Imaging [WITHDRAWN]	_	[\$5 million]
USC	Catalysis for Renewable Fuels	1	\$3 million
USC	Innovation and Commercialization	[See 03-04]	\$2.5 million
USC/Coastal Carolina	Tourism & Economic Development	1	\$2 million
MUSC	Gastrointestinal Cancer Diagnostics	25	\$5 million
MUSC/USC	Cancer Drug Discovery	4	\$5 million
MUSC	26	\$4.5 million	
Total Awarded in 2004-2005		10	\$22 million

¹Revised to three chairs by act of the SmartState Review Board on January 12, 2009.

²Revised to two chairs by act of the SmartState Review Board on February 9, 2015.

³Revised to two chairs by act of the SmartState Review Board on February 23, 2010.

⁴The The Hydrogen Economy Center was approved during 2003-2004. Funding for one half of this Center was provided in 2003-04, the other half in 2004-2005. In 2014, the name changed to the SmartState Center for Innovation and Commercialization and revised to one chair.

Increased from one to two endowed chairs by act of the SmartState Review Board on September 8, 2008.

⁶Revised to two chairs and relinquished USC as a collaborative partner by act of the SmartState Review Board on February 11, 2014.

14

\$32 million

	Funding Year 2005-2006		
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount
Clemson	Supply Chain Optimization & Logistics	1	\$2 million
Clemson	Urban Ecology and Restoration	1	\$2 million
Clemson	Advanced Fiber-Based Materials	1	\$4 million
Clemson	Molecular Nutrition [WITHDRAWN]	_	[\$2 million]
USC	Solid Oxide Fuel Cells	1	\$3 million
USC/MUSC	Childhood Neurotherapeutics	3	\$5 million
MUSC	Molecular Proteomics in Cardiovascular Disease & Prevention	2	\$5 million
MUSC/USC	Clinical Effectiveness & Patient Safety ⁷	3	\$5 million
Total Awarded in 2005-2006		12	\$26 million
	T 1' V 2007 2005		
	Funding Year 2006-2007		
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount
			-
(fiscal institution first)	Proposal Title	Chairs	Amount
(fiscal institution first) Clemson/MUSC	Proposal Title Health Facilities Design & Testing ⁸ Rehabilitation and Reconstruction	Chairs 2	Amount \$2 million
(fiscal institution first) Clemson/MUSC USC	Proposal Title Health Facilities Design & Testing ⁸ Rehabilitation and Reconstruction Science Strategic Approaches to	Chairs 2 1	\$2 million \$5 million
(fiscal institution first) Clemson/MUSC USC USC	Proposal Title Health Facilities Design & Testing ⁸ Rehabilitation and Reconstruction Science Strategic Approaches to the Generation of Electricity	Chairs 2 1	\$2 million \$5 million \$5 million
(fiscal institution first) Clemson/MUSC USC USC USC/MUSC/Clemson	Proposal Title Health Facilities Design & Testing ⁸ Rehabilitation and Reconstruction Science Strategic Approaches to the Generation of Electricity Healthcare Quality	Chairs 2 1 2 2 2 2	\$2 million \$5 million \$5 million \$5 million

Total Awarded in 2006-2007

On September 9, 2008, the SmartState Review Board approved a revision to this proposal which relinquished Clemson University as a collaborative partner and transferred the Chair at Clemson to MUSC.

8The state award total for this Center was revised from \$5 million to \$2 million by the SmartState Review Board on June 11, 2012.

9The SeniorSMART Center of Economic Excellence was approved in 2007-2008. Funding was provided from 2006-2007 dollars.

SC Centers of Economic Excellence Funded Proposals (continued)

	Funding Year 2007-2008							
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount					
Clemson	Optoelectronics	1	\$2 million					
Clemson	CyberInstitute	1	\$2 million					
USC	Environmental Nanoscience and Risk	1	\$3 million					
USC	Nuclear Science and Energy	1	\$3 million					
MUSC	Renal Disease Biomarker	2	\$5 million					
MUSC/Clemson	Cancer Stem Cell Biology	2	\$5 million					
MUSC/USC/Clemson	Advanced Tissue Biofabrication	3	\$5 million					
MUSC/USC/SCSU	Cancer Disparities ¹⁰	3	\$3.6 million					
MUSC/USC	Medication Safety & Efficacy ¹¹	1	\$2 million					
Total Awarded in 2007-2008 15 \$3								
	Funding Year 2008-2009							
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount					
Clemson	Tissue Systems Characterization [WITHDRAWN]	<u> </u>	[\$3 million]					
USC	General Atomics Center for Development of Transformational Nuclear Technologies	1	\$3 million					
USC/MUSC	Healthful Lifestyles ¹²	2	\$3 million					
MUSC	Lipidomics, Pathobiology and Therapy	2	\$5 million					
Total Awarded in 2008-2009		5	\$11 million					
	Funding Year 2009-2010							
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount					
Clemson	Sustainable Development	1	\$4 million					
USC	Data Analysis	1	\$2 million					
MUSC	Inflammation and Fibrosis Research	2	\$5 million					
Total Awarded in 2009-2010		4	\$11 million					

¹⁰The Cancer Disparities Center of Economic Excellence was approved in 2008-2009. Funding was provided from 2007-2008 dollars.

 $^{^{11}}$ The Medication Safety & Efficacy Center was approved in 2008-2009. Funding was provided from 2007-2008 dollars. 12 The Healthful Lifestyles Center of Economic Excellence was approved in 2009-2010 with funding from 2008-2009 dollars.

SC Centers of Economic Excellence Funded Proposals (continued)

Funding Year 2012-2013								
Institution (fiscal institution first)	Proposal Title	Endowed Chairs	Proposal Amount					
Clemson	Smart Grid Technology	1	\$2 million					
USC	Multifunctional Materials and Structures	1	\$2 million					
MUSC	Translational Biomedical Informatics	1	\$2 million					
Total Awarded in 2012-2013		3	\$6 million					

Program Totals ¹	
TOTAL LOTTERY APPROPRIATIONS (2003-2008)	\$180 million
ACCRUED PROGRAM INTEREST USED FOR ADDITIONAL AWARDS *	\$17.6 million
* As permitted by S.C. 2-75-30(A).	
TOTAL FUNDS AWARDED (2003-2013)	\$197.6 million

	Research Institution Totals									
Institution	Centers Awarded	Chairs Created	Chairs Appointed (Remaining to be Appointed)	State Funds Drawn						
Clemson University	13	16	13 (3)	\$43,000,000						
University of South Carolina	18	28	24 (4)	\$66,500,000						
Medical University of South Carolina	20	41	34 (7)	\$88,100,000						
TOTALS	51	85	71 (14)	\$197.6 million						

¹Program totals are as of fiscal year end June 30, 2017. For Research Institution Totals, Centers Awarded and State Funds Drawn for each institution are tallied on the fiscal agent in cases of joint proposals. Chairs are tallied based on the assigned institution as of November 2018. For updated information on Centers and program totals, contact CHE or see www.smartstaesc.org.

INDEPENDENT AUDITOR'S REPORT

To the Review Board South Carolina Centers of Economic Excellence Columbia, South Carolina

Report on the Financial Statement

We have audited the total columns for Clemson University, the Medical University of South Carolina, and the University of South Carolina included in the accompanying Statement of Program Revenues, Expenditures and Changes in Fund Balances of the **South Carolina Centers of Economic Excellence** for the year ended June 30, 2018, and the related notes (the financial statement).

Management's Responsibility for the Financial Statement

Management is responsible for the preparation and fair presentation of this financial statement in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statement that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express opinions on the financial statement based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Opinions

In our opinion, the financial statement referred to above presents fairly, in all material respects, the revenues, expenditures and changes in fund balances of each university within the South Carolina Centers of Economic Excellence for the year ended June 30, 2018, in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

We draw attention to Note 2 to the financial statement, which describes that the accompanying financial statement was prepared for the purpose of complying with the South Carolina Research Centers of Economic Excellence Act and are not intended to be a complete presentation of the South Carolina Centers of Economic Excellence's financial position. Our opinions are not modified with respect to this matter.

Other Matters

Other Information

Our audit was conducted for the purpose of forming opinions on the total column for each university in the financial statement. The supplementary information, as presented in the statement and as listed in the table of contents, and the transmittal letter, are presented for purposes of additional analysis and are not a required part of the financial statement.

The supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statement. Such information has been subjected to the auditing procedures applied in the audit of the financial statement and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statement or to the financial statement itself, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statement as a whole.

The transmittal letter has not been subjected to the auditing procedures applied in the audit of the financial statement, and accordingly, we do not express an opinion or provide any assurance on it.

Columbia, South Carolina December 20, 2018

SOUTH CAROLINA CENTERS OF ECONOMIC EXCELLENCE STATEMENT OF PROGRAM REVENUES, EXPENDITURES AND CHANGES IN FUND BALANCES - CONSOLIDATED SUMMARY YEAR ENDED JUNE 30, 2018

				Clemson U				Medical University of South Carolina					
	State		Non-State	Non-Sta		Endowment	_	State	Non-State	Non-State	Endowment		
	Endowment		ndowment	Expenda	able	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Tota	al
Contribution Revenue													
Non-state matching funds	\$ 1,01	1 \$	60,078	\$	-	\$ -	\$ 61,089	\$ -	\$ -	\$ -	\$ 354,993	\$ 35	354,993
Other contributions/revenue		-	-		-	-	_	-	-	-	-		-
Total contribution revenue	1,01	1	60,078		-		61,089		-	-	354,993	35	354,993
Investment Income													
Realized gain (loss)		-	-		-	1,048,566	1,048,566	-	-	-	24,437,347	24,43	137,347
Unrealized gain (loss)		-	-		-	8,198,221	8,198,221	-	-	-	(13,575,293)	(13,57	575,293
Endowment income		-	-		-	(101,259)	(101,259)	-	-	-	1,110,756	1,11	110,756
Total investment income (loss)		= =	-			9,145,528	9,145,528	-			11,972,810	11,97	72,810
Total revenue	1,01	1	60,078			9,145,528	9,206,617				12,327,803	12,32	327,803
Expenditures													
Personal services		_	_		_	1,478,330	1,478,330		_	_	2,501,583	2.50	501,583
Fringe		-	_		-	428,277	428,277		-	-	858,957		358,957
Travel		-	_			145,532	145,532	-	-	-	81,387		81,387
Subrecipients		-	_				_	-	-	115,000	(15,506)	9	99,494
Supplies		-	_			88,664	88,664	-	-	-	475,867		175,867
Contractual		-	_		-	-	-	-	-	-	1,357,710		357,710
Tuition assistance		-	_		-	86,188	86,188	-	-	-	-	,	٠.
Fixed charges		-	-					-	-	_	64,139	(64,139
Administrative fees		-	-	1	1,000	438,571	439,571	-	-	-	-		
Other		-	_		-			-	-	-	290,694	29	290,694
Professional & other fees		-	-			-		-	-	-	311,741	31	311,741
Equipment		-			-	90,257	90,257	-	-	-	935,440	93	35,440
Total expenditures	-	ΞZ			1,000	2,755,819	2,756,819			115,000	6,862,012		77,012
Excess (deficiency) of revenues over													
(under) expenditures	1,01	1	60,078	(1	(000,	6,389,709	6,449,798	_	_	(115,000)	5,465,791	5.3	350,791
(anasi) experianares			30,0.3		,,,,,,	0,000,100				(1.10,000)	0,100,101		
Cumulative Program Fund Balances													
Beginning Fund Balances as													
Previously Reported	43,000,000	0	35,487,523	156	5,980	33,101,295	111,745,798	88,099,999	34,996,979	12,221,288	25,055,890	160.37	374,156
1 Toviously Reported	10,000,00		00, 101,020	100	,,000	00,101,200	111,140,100	00,000,000	01,000,070	12,221,200	20,000,000	100,0	-1,100
Prior Period Adjustment			-								506,560	50	506,560
Fund Polongo June 20, 2017													
Fund Balance - June 30, 2017, as restated	43,000,000	0	35,487,523	450	5,980	33,101,295	111 745 700	88,099,999	34,996,979	12,221,288	25,562,450	460.00	380,716
as restated	43,000,000	<u> </u>	35,467,323		0,800	33,101,295	111,745,798	00,099,999	34,990,979	12,221,200	25,502,450	100,88	100,710

See notes to financial statements.

SOUTH CAROLINA CENTERS OF ECONOMIC EXCELLENCE STATEMENT OF PROGRAM REVENUES, EXPENDITURES AND CHANGES IN FUND BALANCES - CONSOLIDATED SUMMARY YEAR ENDED JUNE 30, 2018

						7.1.0 111.10					
	State Endowment	Non-State Endowment	versity of South Ca Non-State Expendable	Endowment Earnings	Total	State Endowment	Non-State Endowment	Non-State Expendable	Endowment Earnings	Total	
	LIIGOWIIICIIL	LINOWINGIN	Liperidable	Laililiga	Iotai	Lindowilletit	LIIdowillellt	Lybelldable	Lamings	I Otal	
Contribution Revenue											
Non-state matching funds	\$ -	\$ 3,620	\$ 8,000	\$ -	\$ 11,620	\$ 1,011	\$ 63,698	\$ 8,000	\$ 354,993	\$ 427,702	
Other contributions/revenue	-	-	7,728	37,328	45,056	-	-	7,728	37,328	45,056	
Total contribution revenue		3,620	15,728	37,328	56,676	1,011	63,698	15,728	392,321	472,758	
Investment Income											
Realized gain (loss)	_	_	_	1,415,180	1,415,180	_	_	_	26.901.093	26,901,093	
Unrealized gain (loss)	_	_	_	3,422,209	3,422,209		_	_	(1,954,863)	(1,954,863)	
Endowment income	_	_	11,475	484,102	495,577		_	11,475	1,493,599	1,505,074	
Total investment income (loss)			11,475	5,321,491	5,332,966			11,475	26,439,829	26,451,304	
Total revenue		3,620	27,203	5,358,819	5,389,642	1,011	63,698	27,203	26,832,150	26,924,062	
Expenditures											
Personal services	-	-	3,719	2,277,951	2,281,670		-	3,719	6,257,864	6,261,583	
Fringe	-	-	-	299,006	299,006		-	-	1,586,240	1,586,240	
Travel	-	-	5,157	225,877	231,034	-	-	5,157	452,796	457,953	
Subrecipients	-	-	-	-	-	-	-	128,679	263,342	392,021	
Supplies	-	-	13,679	278,848	292,527	-	-	-	564,531	564,531	
Contractual	-	-	-	-	-	-	-	3,000	1,501,474	1,504,474	
Tuition assistance	-	-	3,000	143,764	146,764	-	-	-	86,188	86,188	
Fixed charges	-	-	-	-	-	-	-	-	64,139	64,139	
Administrative fees	-	-	-	423,284	423,284	-	-	1,000	861,855	862,855	
Other	-	-	42,221	1,054,118	1,096,339	-	-	42,221	1,344,812	1,387,033	
Professional & other fees	-	-		-		-	-	-	311,741	311,741	
Equipment	-		1,617	413,711	415,328	-	-	1,617	1,439,408	1,441,025	
Total expenditures			69,393	5,116,559	5,185,952			185,393	14,734,390	14,919,783	
Excess (deficiency) of revenues over											
(under) expenditures		3,620	(42,190)	242,260	203,690	1,011	63,698	(158,190)	12,097,760	12,004,279	
(222)			(12,100)					(100,100)			
Cumulative Program Fund Balances											
Beginning Fund Balances as											
Previously Reported	66,500,000	29,808,659	1,639,395	14,046,403	111,994,457	197,599,999	100,293,161	14,017,663	72,203,588	384,114,411	
Prior Period Adjustment				60,785	60,785				567,345	567,345	
Fund Balance - June 30, 2017,											
as restated	66,500,000	29,808,659	1,639,395	14,107,188	112,055,242	197,599,999	100,293,161	14,017,663	72,770,933	384,681,756	
Fund Balance - June 30, 2018	\$ 66,500,000	\$ 29,812,279	\$ 1,597,205	\$ 14,349,448	\$ 112,258,932	\$ 197,601,010	\$ 100,356,859	\$ 13,859,473	\$ 84,868,693	\$ 396,686,035	

See notes to financial statements.

NOTES TO FINANCIAL STATEMENTS YEAR END JUNE 30, 2018

NOTE 1. DESCRIPTION OF PROGRAM

The South Carolina Research Centers of Economic Excellence Act (the Act) was introduced by Chapter 75 of Act No. A356 and passed by the South Carolina General Assembly during the 2002 legislative session. The Act was established to create the South Carolina Centers of Economic Excellence (the Program or SmartState) and the Centers of Excellence Matching Endowment, which originally was to be funded annually by appropriations from the South Carolina Education Lottery in an aggregate amount not to exceed \$200 million by 2010. During the year ended June 30, 2009, the South Carolina General Assembly revised the Act to provide for \$30 million in guaranteed funding each year if (a) the lottery scholarships have been funded, and (b) at least 80% of all appropriations have been awarded by the Review Board through the most recent previous fiscal year. In addition, the Act created the Research Centers of Excellence Review Board (the Review Board), which is responsible for awarding state matching funds, for oversight and operation of the fund, and for various accountability requirements established in the statute for the Program. The Review Board consists of eleven members. Of these eleven members, three must be appointed by the Governor of South Carolina, three must be appointed by the President Pro Tempore of the South Carolina Senate, three must be appointed by the Speaker of the South Carolina House of Representatives, one member each must be appointed by the Chair of the Senate Finance Committee and the Chair of the House Ways and Means Committee. The Presidents of the senior research universities of the State of South Carolina (Clemson University, the Medical University of South Carolina, and the University of South Carolina) serve as ex-officio non-voting members.

The purpose of the Act is to create incentives for the senior research universities of South Carolina to raise capital from the private sector to fund endowments for professorships in research areas targeted to create well-paying jobs and enhanced economic opportunities for the people of South Carolina. Non-state funds are used to match dollar-for-dollar funds appropriated by the General Assembly from the South Carolina Education Lottery. The program's intent is to provide \$30 million annually in South Carolina Education Lottery appropriations if (a) the lottery scholarships have been funded, and (b) at least 80% of all appropriations have been awarded by the Review Board through the most recent previous fiscal year. These state appropriations are to be matched by the institutions.

The endowed professorships are awarded to the senior research universities through a competitive application process, which encourages collaboration among the three research universities as well as with other South Carolina institutions of higher education. Awards from the Centers of Excellence Matching Endowment are to be not less than \$2 million and not more than \$5 million. Non-state matching funds are to be raised exclusively from sources other than South Carolina tax dollars, and committed and raised subsequent to January 1, 2002. The Research Centers of Economic Excellence Act was amended March 17, 2004, adding Section 90, which allows the research institutions to use federal funds received after July 1, 2003, as non-state matching funds. The Research Centers of Economic Excellence Act was further amended on June 25, 2008, adding Section 100, which allows the Review Board to use a portion (as determined by the Review Board) of the non-state match to pay for Center operating costs and which requires that the full state award of any dissolved or withdrawn Center be returned to the Centers of Excellence Matching Endowment. Section 110 was also added on June 25, 2008, which provided the eligibility of in-kind contributions as non-state matches.

NOTES TO FINANCIAL STATEMENTS YEAR END JUNE 30, 2018

NOTE 1. DESCRIPTION OF PROGRAM (CONTINUED)

In 2010, the General Assembly amended the Research Centers of Economic Excellence Act to create a new type of SmartState Award to be made in concert with the South Carolina Department of Commerce. One-quarter of the unallocated Centers of Excellence Matching Endowment funds is dedicated for funding such "SmartState Commerce Awards." SmartState Commerce Awards may not individually exceed \$2 million and do not require the dollar-for-dollar non-state match of Standard SmartState awards. In place of a matching requirement, the Secretary of Commerce is required to certify that a "significant capital investment" has been made in the related research field of a proposed SmartState Commerce Award professorial endowment; the intent of SmartState Commerce Award endowment is to "directly support the industry." These revisions became effective January 1, 2011.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Measurement Focus, Basis of Accounting and Financial Statement Presentation:

The Program's financial statement was prepared solely for the purpose of complying with Chapter 75 Section 2-75-10, the South Carolina Research Centers of Economic Excellence Act. The financial statements are not a complete presentation of the financial statements of the Program but one that is otherwise in accordance with Generally Accepted Accounting Principles.

The Program's fund financial statement is reported using the current financial resources measurement focus and the modified accrual basis of accounting. Revenues are recognized as soon as they are both measurable and available. Revenues are considered to be available when they are collectible within the current period or soon enough thereafter to pay liabilities of the current period. For this purpose, the Program considers revenues to be available if they are collected within 60 days of the end of the current fiscal period. Expenditures generally are recorded when a liability is incurred, as under accrual accounting.

Property and Equipment:

Property and equipment purchased with program funds are recorded as expenditures in the statement of program revenues, expenditures and changes in fund balances and deemed to be the property of the respective research institution.

Assets Available for Program Use:

State funds committed for Program use are permanently restricted, as well as 30% of the non-state matching funds of each Center of Economic Excellence, as endowment funds. Earnings from the endowments funds may be expended for direct program purposes, as well as any non-state matching funds that exceed the 30% endowment requirement. In-kind contributions of real property, equipment, supplies and other expendable property, and the value of goods and services directly benefiting and specifically identifiable to a project or program may be used to satisfy non-state matching requirements, but may not account for more than 70% of the non-state match total for each proposal.

NOTES TO FINANCIAL STATEMENTS YEAR END JUNE 30, 2018

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of Estimates:

Total

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of fund balance at the date of the financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from those estimates.

Federal Grants Used as Non-state Matching Funds:

Federal grants used as non-state matching funds by the research institutions are not reflected in the statements of program revenues and expenditures. Such funds are maintained separately from the Program by the research institutions. See Note 4 for additional information.

Realized and Unrealized Investment Gains and Losses and Investment Income:

Realized and unrealized gains and losses and income from the investments in the master investment accounts at each of the Research Institution Foundations and at each of the Research Institutions are allocated periodically, including at year end, to the individual Smart State accounts based on the relationship of the fair value of each individual account to the total fair value of the master investment accounts, and adjusted for additions to or deductions from those accounts.

NOTE 3. ASSETS MAINTAINED BY RESEARCH INSTITUTIONS/FUND BALANCE

The fund balance resulting from program activities are maintained by the research institutions, and is held by the universities, their respective foundations, or by the State Treasurer. At June 30, 2018, fund balance consisted of cash and investments maintained by the research institutions for program purposes and was as follows:

\$ 396,686,035

Clemson University	\$ 118,195,596
Medical University of South Carolina	166,231,507
University of South Carolina	112,258,932

NOTES TO FINANCIAL STATEMENTS YEAR END JUNE 30, 2018

NOTE 4. PROPOSALS USING FEDERAL GRANTS FOR NON-STATE MATCHING FUNDS

As described in Note 2, federal grants are eligible for use as non-state matching funds, but are not included in the statements of program revenues and expenditures. The following table displays the total federal awards that have qualified as non-state matching funds and those that have been used toward the non-state match for each proposal as of June 30, 2018:

Federal Grants Used as

Non-State Non-				rederal Gra		
Institution Proposal Match As Non-State As Non-State Clemson Optical Materials \$ 772,961 \$ 772,961 Clemson Sustainable Development 1,313,439 1,000,000 Clemson Advanced Fiber-Based Materials 310,000 310,000 MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Brain Imaging 1,336,000 1,336,000			1		atchii	ng Funds
Institution						
Institution Proposal Match Match Clemson Optical Materials \$ 772,961 \$ 772,961 Clemson Sustainable Development 1,313,439 1,000,000 Clemson Advanced Fiber-Based Materials 310,000 310,000 MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Gastrointestinal Cancer 1,956,478 1,476,419 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 <td< th=""><th></th><th></th><th>Q</th><th>ualifying</th><th>An</th><th>nount Used</th></td<>			Q	ualifying	An	nount Used
Clemson Optical Materials \$ 772,961 \$ 772,961 Clemson Sustainable Development 1,313,439 1,000,000 Clemson Advanced Fiber-Based Materials 310,000 310,000 MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Gastrointestinal Cancer 1,956,478 1,476,419 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 <tr< th=""><th></th><th></th><th>As</th><th>Non-State</th><th>As</th><th>Non-State</th></tr<>			As	Non-State	As	Non-State
Clemson Sustainable Development 1,313,439 1,000,000 Clemson Advanced Fiber-Based Materials 310,000 310,000 MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC	<u>Institution</u>	Proposal	_	Match		Match
Clemson Advanced Fiber-Based Materials 310,000 310,000 MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Abuscutures 1,444,820 1,444,820 USC Nanostructures 1,444,820 1,444,820 USC </td <td>Clemson</td> <td>Optical Materials</td> <td>\$</td> <td>772,961</td> <td>\$</td> <td>772,961</td>	Clemson	Optical Materials	\$	772,961	\$	772,961
MUSC Proteomics 1,375,919 1,265,030 MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Solid Oxide Fuel Cel	Clemson	Sustainable Development		1,313,439		1,000,000
MUSC Marine Genomics 2,927,730 2,208,577 MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 1,106,179 1,106,179 USC Childhood N	Clemson	Advanced Fiber-Based Materials		310,000		310,000
MUSC Translational Cancer Therapeutics 6,174,089 3,001,905 MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Nanostructures 1,444,820 1,444,820 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 1,106,179 1,106,179 USC<	MUSC	Proteomics		1,375,919		1,265,030
MUSC Cancer Drug Discovery 6,292,518 3,395,490 MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC	MUSC	Marine Genomics		2,927,730		2,208,577
MUSC Gastrointestinal Cancer 3,221,264 2,438,472 MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nuclear Science and Energy <td>MUSC</td> <td>Translational Cancer Therapeutics</td> <td></td> <td>6,174,089</td> <td></td> <td>3,001,905</td>	MUSC	Translational Cancer Therapeutics		6,174,089		3,001,905
MUSC Vision Science 1,956,478 1,476,419 MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the	MUSC	Cancer Drug Discovery		6,292,518		3,395,490
MUSC Tobacco-Related Malignancies 3,221,264 2,402,853 MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Gastrointestinal Cancer		3,221,264		2,438,472
MUSC Renal Disease Biomarkers 268,520 254,406 MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Vision Science		1,956,478		1,476,419
MUSC Cancer Stem Cell 2,457,288 1,851,876 MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Tobacco-Related Malignancies		3,221,264		2,402,853
MUSC Advanced Tissue Biofabrication 2,578,100 2,502,146 MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and	MUSC	Renal Disease Biomarkers		268,520		254,406
MUSC Lipidomics 1,624,983 1,523,925 USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Cancer Stem Cell		2,457,288		1,851,876
USC Nanostructures 1,444,820 1,444,820 USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Advanced Tissue Biofabrication		2,578,100		2,502,146
USC Brain Imaging 1,336,000 1,336,000 USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	MUSC	Lipidomics		1,624,983		1,523,925
USC Polymer Nanocomposites 2,020,110 2,020,110 USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and	USC	Nanostructures		1,444,820		1,444,820
USC Hydrogen Fuel Cell Economy 661,451 661,451 USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and	USC	Brain Imaging		1,336,000		1,336,000
USC Renewable Fuel Cells 970,516 970,516 USC Solid Oxide Fuel Cells 1,106,179 1,106,179 USC Childhood Neurotherapeutics 1,243,106 1,243,106 USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and	USC	Polymer Nanocomposites		2,020,110		2,020,110
USC Solid Oxide Fuel Cells 1,106,179 USC Childhood Neurotherapeutics 1,243,106 USC Data Analysis 533,444 USC Nanoenvironmental Research and Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Hydrogen Fuel Cell Economy		661,451		661,451
USC Childhood Neurotherapeutics 1,243,106 USC Data Analysis 533,444 USC Nanoenvironmental Research and Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Renewable Fuel Cells		970,516		970,516
USC Data Analysis 533,444 533,444 USC Nanoenvironmental Research and Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Solid Oxide Fuel Cells		1,106,179		1,106,179
USC Nanoenvironmental Research and Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Childhood Neurotherapeutics		1,243,106		1,243,106
Assessment 731,822 731,822 USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Data Analysis		533,444		533,444
USC Nuclear Science and Energy 848,512 842,408 USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531	USC	Nanoenvironmental Research and				
USC General Atomics Center for the Development of Translational Nuclear Technology 1,105,531 1,105,531		Assessment		731,822		731,822
of Translational Nuclear Technology 1,105,531 1,105,531	USC	Nuclear Science and Energy		848,512		842,408
<u> </u>	USC	General Atomics Center for the Development				
\$ 46,496,044 \$ 36.399.447		of Translational Nuclear Technology		1,105,531		1,105,531
			\$	46,496,044	_\$	36,399,447

NOTES TO FINANCIAL STATEMENTS YEAR END JUNE 30, 2018

NOTE 5. RESTATEMENT OF PRIOR PERIOD FUND BALANCES

Management became aware in 2018 that at June 30, 2017, the consolidated fund balances were understated. At June 30, 2017, USC fund balances for Childhood Neuro Therapeutics were understated by \$60,785 due to erroneously not reporting a fund; MUSC fund balances for Medication Safety and Efficacy were understated by \$81,046; fund balances for Advance Tissue Bio-fabrication were understated by \$318,485; and fund balances for Drug Discovery in Cancer were understated by \$54,544. These adjustments were required due to not recording in the MUSC financial statements fund balances for Centers at Clemson University and the University of South Carolina where MUSC was the fiscal agent. In addition, the fund balances for Marine Genomics were understated by \$52,485, which was caused by a formula error in the internally prepared financial statements. As result, the consolidated cumulative fund balances for the year ended June 30, 2017 were restated. A summary of the understatement is shown below:

	As	As
Fund Balances	Reported Adjustment	Restated
USC	\$ 111,994,457 \$ 60,785	\$ 112,055,242
MUSC	\$ 160,374,156 \$ 506,560	\$ 160,880,716

		Automotive Design and Development						Automotive Manufacturing Integration				
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment			
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total		
Contribution Revenue												
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		
Total contribution revenue								-		-		
Investment Income							_					
Realized gain (loss)	-	-	-	102,896	102,896	-	-	-	133,613	133,613		
Unrealized gain (loss)	-	-	-	814,091	814,091	-	-	-	1,021,228	1,021,228		
Endowment income				(10,693)	(10,693)	_			(19,134)	(19,134)		
Total investment income (loss)				906,294	906,294	-			1,135,707	1,135,707		
Total revenue				906,294	906,294	<u>·</u>			1,135,707	1,135,707		
Expenditures												
Personal services	-	-	-	155,500	155,500	-	-	-	158,918	158,918		
Fringe	-	-	-	44,120	44,120	-	-	-	44,706	44,706		
Travel	-	-		13,397	13,397	-	-	-	18,514	18,514		
Supplies	-	-	-	4,973	4,973	-	-	-	4,058	4,058		
Tuition assistance	-	-	-	1,710	1,710	-	-	-	7,032	7,032		
Other	-	-	-	23,732	23,732	-	-	-	28,753	28,753		
Equipment			-	6,226	6,226				1,060	1,060		
Total expenses		-		249,658	249,658				263,041	263,041		
Excess (deficiency) of revenues												
over (under) expenditures				656,636	656,636				872,666	872,666		
Cumulative Program Fund Balances												
Beginning Fund Balances as Previously Reported	5,000,000	2,845,991		3,187,447	11,033,438	5,000,000	5,000,000	_	4,110,844	14,110,844		
, ,	1,11,11	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			,,	-,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		, -,-	, -,-		
Prior Period Adjustment			-	-	<u>-</u>	-	<u>-</u>		<u>-</u>			
Fund Balance - June 30, 2017,	5,000,000	0.045.004		0.407.447	44 000 400	5 000 000	5 000 000		4.440.044	44.440.044		
as restated	5,000,000	2,845,991		3,187,447	11,033,438	5,000,000	5,000,000		4,110,844	14,110,844		
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 2,845,991	\$ -	\$ 3,844,083	\$ 11,690,074	\$ 5,000,000	\$ 5,000,000	\$ -	\$ 4,983,510	\$ 14,983,510		

		Autom	notive Systems Int	ogration				Optical Materials		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue					-					
Investment Income										
Realized gain (loss)	-	-	-	143,622	143,622	-	-	-	102,545	102,545
Unrealized gain (loss)	-	-	-	1,096,087	1,096,087	-	-	-	822,648	822,648
Endowment income				(20,840)	(20,840)				(8,945)	(8,945)
Total investment income (loss)				1,218,869	1,218,869	-			916,248	916,248
Total revenue				1,218,869	1,218,869	<u>·</u>			916,248	916,248
Expenditures										
Personal services	-	-	-	163,220	163,220	-	-	-	224,873	224,873
Fringe	-	-	-	45,893	45,893	-	-	-	73,258	73,258
Travel	-	-		8,851	8,851	-	-	-	23,933	23,933
Supplies	-	-	-	615	615	-	-	-	18,493	18,493
Tuition assistance	-	-	-	5,120	5,120	-	-	-	5,502	5,502
Other	-	-	-	17,626	17,626	-	-	1,000	51,071	52,071
Equipment				15,919	15,919					
Total expenses		-		257,244	257,244			1,000	397,130	398,130
Excess (deficiency) of revenues										
over (under) expenditures				961,625	961,625			(1,000)	519,118	518,118
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported	5,000,000	5,000,000	114,921	5,150,398	15,265,319	5,000,000	3,050,852	11,883	3,534,946	11,597,681
Prior Period Adjustment										
Fund Balance - June 30, 2017, as restated	5,000,000	5,000,000	114,921	5,150,398	15,265,319	5,000,000	3,050,852	11,883	3,534,946	11,597,681
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 5,000,000	\$ 114,921	\$ 6,112,023	\$ 16,226,944	\$ 5,000,000	\$ 3,050,852	\$ 10,883	\$ 4,054,064	\$ 12,115,799

			icle Electronic Sy					ain Optimization a	•	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,011	\$ -	\$ -	\$ -	\$ 1,011
Total contribution revenue					-	1,011				1,011
Investment Income										
Realized gain (loss)	-	-	-	65,962	65,962	-	-	-	53,596	53,596
Unrealized gain (loss)	-	-	-	519,870	519,870	-	-	-	408,838	408,838
Endowment income				(7,102)	(7,102)				(7,478)	(7,478)
Total investment income (loss)				578,730	578,730	-			454,956	454,956
Total revenue				578,730	578,730	1,011		·	454,956	455,967
Expenditures										
Personal services	-	-	-	186,115	186,115	-	-	-	134,187	134,187
Fringe	-	-	-	52,370	52,370	-	-	-	36,542	36,542
Travel	-	-		14,427	14,427	-	-	-	15,953	15,953
Supplies	-	-	-	10,571	10,571	-	-	-	1,642	1,642
Tuition assistance	-	-	-	12,800	12,800	-	-	-	18,979	18,979
Other	-	-	-	64,248	64,248	-	-	-	2,240	2,240
Equipment				3,807	3,807				5,683	5,683
Total expenses		-		344,338	344,338				215,226	215,226
Excess (deficiency) of revenues										
over (under) expenditures				234,392	234,392	1,011			239,730	240,741
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported	3,000,000	2,000,000		2,002,667	7,002,667	2,000,000	2,000,000	-	1,336,647	5,336,647
Prior Period Adjustment										
Fund Balance - June 30, 2017, as restated	3,000,000	2,000,000		2,002,667	7,002,667	2,000,000	2,000,000		1,336,647	5,336,647
Fund Balance - June 30, 2018	\$ 3,000,000	\$ 2,000,000	\$ -	\$ 2,237,059	\$ 7,237,059	\$ 2,001,011	\$ 2,000,000	¢ _	\$ 1,576,377	\$ 5,577,388

			Ecology and Res					ced Fiber-Based I	Materials	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue										
Investment Income										
Realized gain (loss)	-	-	-	54,587	54,587	-	-	-	98,795	98,795
Unrealized gain (loss)	-	-	-	414,669	414,669	-	-	-	762,907	762,907
Endowment income				(7,319)	(7,319)				(12,476)	(12,476
Total investment income (loss)				461,937	461,937	-			849,226	849,226
Total revenue				461,937	461,937				849,226	849,226
Expenditures										
Personal services	-	-	-	104,814	104,814	-	-	-	188,350	188,350
Fringe	-	-	-	20,812	20,812	-	-	-	59,047	59,047
Travel	-	-		13,040	13,040	-	-	-	18,196	18,196
Supplies	-	-	-	2,996	2,996	-	-	-	408	408
Tuition assistance	-	-	-	4,068	4,068	-	-	-	8,259	8,259
Other	-	-	-	17,239	17,239	-	-	-	22,458	22,458
Equipment				1,459	1,459					
Total expenses		-	<u> </u>	164,428	164,428				296,718	296,718
Excess (deficiency) of revenues										
over (under) expenditures				297,509	297,509				552,508	552,508
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	2,000,000	2,000,000	-	1,647,677	5,647,677	4,000,000	3,482,500	30,176	3,342,990	10,855,666
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	2,000,000	2,000,000		1,647,677	5,647,677	4,000,000	3,482,500	30,176	3,342,990	10,855,666
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 2,000,000	\$ -	\$ 1,945,186	\$ 5,945,186	\$ 4,000,000	\$ 3,482,500	\$ 30,176	\$ 3,895,498	\$ 11,408,174

		Health F	acilities Design ar	nd Testing				Optoelectronics	•	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue										
Investment Income										
Realized gain (loss)	_	-	-	52,586	52,586	-	-	_	54,705	54,705
Unrealized gain (loss)	-	-	-	473,774	473,774	-	-	-	415,124	415,124
Endowment income	-	-	-	3,262	3,262	-	-	-	(8,021)	(8,021)
Total investment income (loss)				529,622	529,622	_			461,808	461,808
Total revenue				529,622	529,622				461,808	461,808
Expenditures										
Personal services	-	-	-	30,709	30,709	-	-	-	47,134	47,134
Fringe	-	-	-	11,702	11,702	-	-	-	10,400	10,400
Travel	-	-		3,872	3,872	-	-	-	11,598	11,598
Supplies	-	-	-	701	701	-	-	-	43,254	43,254
Tuition assistance	-	-	-	13,148	13,148	-	-	-	9,570	9,570
Other	-	-	-	114,661	114,661	-	-	-	81,058	81,058
Equipment				2,579	2,579				53,524	53,524
Total expenses		-		177,372	177,372				256,538	256,538
Excess (deficiency) of revenues										
over (under) expenditures				352,250	352,250				205,270	205,270
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	2,000,000	2,000,000	-	2,050,313	6,050,313	2,000,000	2,006,799	-	1,543,024	5,549,823
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	2,000,000	2,000,000		2,050,313	6,050,313	2,000,000	2,006,799		1,543,024	5,549,823
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 2,000,000	\$ -	\$ 2,402,563	\$ 6,402,563	\$ 2,000,000	\$ 2,006,799	\$ -	\$ 1,748,294	\$ 5,755,093

			Cyber-Institute				Su	stainable Develop	ment	
	State	Non-State	Non-State	Endowment	-	State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ 60,078	\$ -	\$ -	\$ 60,078	\$ -	\$ -	\$ -	\$ -	\$
Total contribution revenue		60,078			60,078					
Investment Income										
Realized gain (loss)	-	_	_	42,025	42,025	-	-	_	93,840	93,840
Unrealized gain (loss)	-	-	-	333,546	333,546	-	-	-	733,444	733,444
Endowment income	-	-	-	(1,604)	(1,604)	-	-	-	(10,183)	(10,183
Total investment income (loss)	-			373,967	373,967	_			817,101	817,101
Total revenue		60,078		373,967	434,045				817,101	817,101
Expenditures										
Personal services	-	-	_	3,889	3,889	-	-	_	80,621	80,621
Fringe	-	-	_	1,209	1,209		-	_	28,218	28,218
Travel	-	-		· 1			-	-	3,751	3,751
Supplies	-	-	-	-	-	-	-	-	953	953
Tuition assistance	-	-	-	-	-	-	-	-	-	
Other	-	-	-	-	-	-	-	-	15,485	15,485
Equipment			-	_	-					
Total expenses			·	5,098	5,098				129,028	129,028
Excess (deficiency) of revenues										
over (under) expenditures		60,078		368,869	428,947				688,073	688,073
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	2,000,000	1,089,923	-	1,386,105	4,476,028	4,000,000	3,011,458	-	3,066,631	10,078,089
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	2,000,000	1,089,923		1,386,105	4,476,028	4,000,000	3,011,458		3,066,631	10,078,089
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 1,150,001	\$ -	\$ 1,754,974	\$ 4,904,975	\$ 4,000,000	\$ 3,011,458	\$ -	\$ 3,754,704	\$ 10,766,162

		Dι	ike Energy Smart	Grid			Tot	al - Clemson Univ	ersity	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,011	\$ 60,078	\$ -	\$ -	\$ 61,089
Total contribution revenue	-	-			-	1,011	60,078	-		61,089
Investment Income							_			
Realized gain (loss)	-	-	-	49,794	49,794	-	-	-	1,048,566	1,048,566
Unrealized gain (loss)	-	-	-	381,995	381,995	-	-	-	8,198,221	8,198,221
Endowment income	-	-	-	9,274	9,274	-	-	-	(101,259)	(101,259
Total investment income (loss)				441,063	441,063				9,145,528	9,145,528
Total revenue				441,063	441,063	1,011	60,078		9,145,528	9,206,617
Expenditures										
Personal services	-	-	-	-		-	-	-	1,478,330	1,478,330
Fringe	-	-	-	-		-	-	-	428,277	428,277
Travel	-	-			-	-	-	-	145,532	145,532
Supplies	-	-	-	-	-	-	-	-	88,664	88,664
Tuition assistance	-	-	-	- '	-	-	-	-	86,188	86,188
Other	-	-	-	-	-	-	-	1,000	438,571	439,571
Equipment				-	-				90,257	90,257
Total expenses	-		<u> </u>		-			1,000	2,755,819	2,756,819
Excess (deficiency) of revenues				444.000		4.044	00.070	(4.000)	0.000.700	
over (under) expenditures				441,063	441,063	1,011	60,078	(1,000)	6,389,709	6,449,798
Cumulative Program Fund Balances Beginning Fund Balances as										
Previously Reported	2,000,000	2,000,000		741,606	4,741,606	43,000,000	35,487,523	156,980	33,101,295	111,745,798
Prior Period Adjustment										
Fund Balance - June 30, 2017, as restated	2,000,000	2,000,000		741,606	4,741,606	43,000,000	35,487,523	156,980	33,101,295	111,745,798
40.004404	2,000,000	2,000,000		7 7 1,000	4,141,000	40,000,000	00,407,020	100,000	55, 101,295	111,140,190
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 2,000,000	\$ -	\$ 1,182,669	\$ 5,182,669	\$ 43,001,011	\$ 35,547,601	\$ 155,980	\$ 39,491,004	\$ 118,195,596

			Proteomics					Neurosciences		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 105	\$ 105
Total contribution revenue									105	105
Investment Income							_			
Realized gain (loss)	-	-	-	1,071,664	1,071,664	-	-	-	824,283	824,283
Unrealized gain (loss)	-	-	-	(616,162)	(616,162)	-	-	-	(473,047)	(473,047)
Endowment income	-	-	-	49,230	49,230	-	-	-	37,978	37,978
Total investment income (loss)				504,732	504,732				389,214	389,214
Total revenue				504,732	504,732				389,319	389,319
Expenditures										
Personal services	-	-	-	167,651	167,651	-	-	_	79,323	79,323
Fringe	-	-	-	42,908	42,908		-	_	28,034	28,034
Travel	-	-		29,033	29,033		-	_	-	· -
Subrecipients	-	-		-	-	-	-	_	-	-
Supplies	-	-	-	1,906	1,906	_	-	_	-	-
Contractual	-	-	-	63,042	63,042	-	-	-	33,030	33,030
Other	-	-	-	5,812	5,812	-	-	-	-	-
Fixed Charges	-	-	-	-	-	-	-	-	-	-
Professional & Other Fees	-	-	-	25,185	25,185	-	-	-	-	-
Equipment	-	-	-	363,385	363,385	-	-	-	-	-
Total expenditures				698,922	698,922				140,387	140,387
Excess (deficiency) of revenues over										
(under) expenditures			<u> </u>	(194,190)	(194,190)				248,932	248,932
Cumulative Program Fund Balances										
Beginning Fund Balances as				_						
Previously Reported	4,000,000	1,254,266	660,098	1,080,798	6,995,162	3,000,000	900,350	770,829	1,068,913	5,740,092
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	4,000,000	1,254,266	660,098	1,080,798	6,995,162	3,000,000	900,350	770,829	1,068,913	5,740,092
			7							

			Marine Genomics	3			R	egenerative Medic	ine	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	_
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	s -	\$ -	\$ -		\$ 500	\$ 500
Total contribution revenue									500	500
Investment Income										
Realized gain (loss)	-	-	-	744,938	744,938	-	-	-	1,087,729	1,087,729
Unrealized gain (loss)	-	-	-	(194,549)	(194,549)	-	-	-	(403,268)	(403,268)
Endowment income				34,521	34,521	_			39,733	39,733
Total investment income (loss)				584,910	584,910	-			724,194	724,194
Total revenue				584,910	584,910	_			724,694	724,694
Expenditures										
Personal services	_	_	_	53,752	53,752		_	_	74,512	74,512
Fringe				19,709	19,709				38,109	38,109
Travel		_	_	358	358			_	4,874	4,874
Subrecipients		_		330	330		_	_	4,074	4,074
Supplies		_					_	_	31,178	31,178
Contractual		_		52,049	52,049			_	62,503	62,503
Other	_	_		76,150	76,150	_	_	_	145,075	145,075
Fixed Charges	_			70,100	70,100	_	_	_	174	174
Professional & Other Fees									46,006	46.006
Equipment	_					_	_	_	517,987	517,987
Total expenditures				202,018	202,018				920,418	920,418
rotal experientares				202,010	202,010				320,410	320,410
Excess (deficiency) of revenues over										
(under) expenditures				382,892	382,892				(195,724)	(195,724)
Overaletive Browner Found Belower										
Cumulative Program Fund Balances										
Beginning Fund Balances as	4 000 000	4 500 000	00.070	4 005 007	0.055.507	F 000 000	0.000.000	(000,004)	0.557.400	0.047.044
Previously Reported	4,000,000	1,500,000	89,970	1,265,627	6,855,597	5,000,000	2,000,000	(239,884)	2,557,198	9,317,314
Prior Period Adjustment				52,485	52,485					
Fund Balance - June 30, 2017,										
as restated	4,000,000	1,500,000	89,970	1,318,112	6,908,082	5,000,000	2,000,000	(239,884)	2,557,198	9,317,314
สร เซรเสเซน	4,000,000	1,500,000	69,970	1,310,112	5,305,052	5,000,000	۷,000,000	(239,004)	2,007,198	5,317,314
Fund Balance - June 30, 2018	\$ 4,000,000	\$ 1,500,000	\$ 89,970	\$ 1,701,004	\$ 7,290,974	\$ 5,000,000	\$ 2,000,000	\$ (239,884)	\$ 2,361,474	\$ 9,121,590

			tional Cancer The					ug Discovery in Ca		
	State	Non-State	Non-State	Endowment	-	State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue				-	-	-	-	-		
Investment Income										
Realized gain (loss)	-	-	-	1,448,381	1,448,381	-	-	-	1,328,402	1,328,402
Unrealized gain (loss)	-	-	-	(828,831)	(828,831)	-	-	-	(761,908)	(761,908)
Endowment income				66,477	66,477				61,123	61,123
Total investment income (loss)				686,027	686,027	<u> </u>			627,617	627,617
Total revenue				686,027	686,027	-			627,617	627,617
Expenditures										
Personal services	_	_	_	220,336	220,336		_	_	208,718	208,718
Fringe				76,084	76,084				53,663	53,663
Travel			_	364	364		_	_	5,458	5,458
Subrecipients				304	304		_	_	3,430	5,450
Supplies				47,338	47,338		_	_	67,216	67,216
Contractual	_	_		60,430	60,430		_	_	89,531	89,531
Other	_	_		00,400	00,400		_	_	1,827	1,827
Fixed Charges	_					_	_	_	232	232
Professional & Other Fees				24,858	24,858				15,781	15,781
Equipment	_			24,000	24,000	_	_	_	7,296	7,296
Total expenditures				429,410	429,410				449,722	449,722
rotal experiantics				425,410	420,410				445,722	445,722
Excess (deficiency) of revenues over										
(under) expenditures	-			256,617	256,617	-	_	-	177,895	177,895
					· · · · · · · · · · · · · · · · · · ·					
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	1,998,095	-	1,613,026	8,611,121	5,000,000	1,604,510	-	1,575,967	8,180,477
Prior Period Adjustment		-							54,544	54,544
Fund Balance - June 30, 2017,										
as restated	5,000,000	1,998,095	_	1,613,026	8,611,121	5,000,000	1,604,510	-	1,630,511	8,235,021
	3,333,300	.,555,556		.,5.5,520	-,,	2,223,300	.,55.,510		.,000,011	-,,
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 1,998,095	\$ -	\$ 1,869,643	\$ 8,867,738	\$ 5,000,000	\$ 1,604,510	\$ -	\$ 1,808,406	\$ 8,412,916

			ntestinal Cancer D					Vision Science		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue		-			-			<u> </u>		
Investment Income										
Realized gain (loss)	-	-	-	1,435,310	1,435,310	-	-	-	1,295,306	1,295,306
Unrealized gain (loss)	-	-	-	(826,963)	(826,963)	-	-	-	(750,079)	(750,079)
Endowment income				65,666	65,666				59,030	59,030
Total investment income (loss)				674,013	674,013				604,257	604,257
Total revenue				674,013	674,013				604,257	604,257
Expenditures										
Personal services		_		217,286	217,286			_	110,652	110,652
Fringe		_		79,913	79,913			_	38,176	38,176
Travel		_		19,915	70,010			_	3,463	3,463
Subrecipients		_				_		_	5,405	3,403
Supplies		_		0		_		_	34,566	34,566
Contractual		_		83,995	83,995	_		_	78,480	78,480
Other	_	_		- 00,000	00,000	_	_	_	910	910
Fixed Charges	_					_		_	-	-
Professional & Other Fees									3,032	3,032
Equipment	_	_				_		_	2,650	2,650
Total expenditures	<u>_</u>			381,194	381,194				271,929	271,929
rotal expenditures				001,104	001,104				271,020	271,020
Excess (deficiency) of revenues over										
(under) expenditures				292,819	292,819				332,328	332,328
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	2,000,000	619,366	1,854,939	9,474,305	4,500,000	1,883,774	1,003,532	1,562,342	8,949,648
, ,	,,,,,	,,,,,,,,		,,	, ,	,,	,===,	,,	, , -	.,,.
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	5,000,000	2,000,000	619,366	1,854,939	9,474,305	4,500,000	1,883,774	1,003,532	1,562,342	8,949,648
Fund Balance - June 30, 2018	\$ 5.000.000	\$ 2,000,000	\$ 619,366	\$ 2,147,758	\$ 9,767,124	\$ 4,500,000	\$ 1,883,774	\$ 1,003,532	\$ 1,894,670	\$ 9.281.976
Fully Balatice - Julie 30, 2018	\$ 5,000,000	φ 2,000,000	φ 019,300	φ 2,141,138	φ 9,/0/,124	φ 4,500,000	φ 1,003,174	φ 1,003,332	φ 1,094,070	\$ 9,281,976

		Clinical Ef	fectiveness and Pa	ntiant Cafaty		Mak	ecular Proteomics	in Cardiavassular	Diagon and Brow	ontion
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	ention
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
	Liidoiiiiidii									
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue					-		_			
Investment Income										
Realized gain (loss)	-	-	-	1,428,324	1,428,324	-	-	-	1,643,195	1,643,195
Unrealized gain (loss)	-	-	-	(819,732)	(819,732)	-	-	-	(944,891)	(944,891)
Endowment income				65,654	65,654				75,488	75,488
Total investment income (loss)				674,246	674,246	<u> </u>			773,792	773,792
Total revenue				674,246	674,246				773,792	773,792
Expenditures										
Personal services	_	_	_	175,632	175,632	_	_	_	151,310	151,310
Fringe	_	_	_	64,424	64,424		_	_	55,476	55,476
Travel	_	_	_	3,993	3,993	_	_	_	3	3
Subrecipients	_	_	_	988	988	_	_	_	-	
Supplies	_	_		760	760	_	_	_	926	926
Contractual	_	_	_	84,006	84,006	_	_	_	96,653	96,653
Other	_	_	_	_	-	_	_	_	10,441	10,441
Fixed Charges	_	-/	_	51	51	_	_	_	17,723	17,723
Professional & Other Fees	_	-		2,067	2,067	_	_	_	-	-
Equipment	_	_ `		4,312	4,312	-	-	-	-	-
Total expenditures	-			336,233	336,233	-			332,532	332,532
Fuence (deficiency) of revenues aver										
Excess (deficiency) of revenues over (under) expenditures				338,013	338,013				441,260	441,260
(under) expenditures				330,013	330,013	<u>-</u>		<u>-</u>	441,200	441,200
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	2,000,000	-	1,449,273	8,449,273	5,000,000	3,518,805	1,197,319	1,075,661	10,791,785
, ,					, ,					, ,
Prior Period Adjustment		<u> </u>								
Fund Balance - June 30, 2017,										
as restated	5,000,000	2,000,000	_	1,449,273	8,449,273	5,000,000	3,518,805	1,197,319	1,075,661	10,791,785
				.,,	-,,			.,,	.,,	
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 2,000,000	\$ -	\$ 1,787,286	\$ 8,787,286	\$ 5,000,000	\$ 3,518,805	\$ 1,197,319	\$ 1,516,921	\$ 11,233,045

			acco-Related Maliç					Stroke		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ 8,410	\$ 8,410	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue				8,410	8,410					
Investment Income				4 400 000	4 400 000				4 550 004	4 550 004
Realized gain (loss)	-	-	-	1,496,993	1,496,993	-	-	-	1,558,391	1,558,391
Unrealized gain (loss)	-	-	-	(863,807)	(863,807)	-	-	-	(893,309)	(893,309)
Endowment income	<u>-</u>			68,478	68,478				71,650	71,650
Total investment income (loss)				701,664	701,664				736,732	736,732
Total revenue				710,074	710,074	-			736,732	736,732
Expenditures										
Personal services	_	_	_	100,678	100,678		_	_	186,738	186,738
Fringe	_	_	_	36,937	36,937		_	_	58,475	58,475
Travel	_	_		33,33.	-		_	_	8,539	8,539
Subrecipients	_	_				_	_	_	-	-
Supplies	_	_		18,432	18,432	_	_	_	4,107	4,107
Contractual	_	_	_	87,915	87,915	_	_	_	- 1,101	-,
Other	_	_	_	949	949	_	_	_	483	483
Fixed Charges				2,062	2,062					
Professional & Other Fees				803	803			_	97,890	97,890
Equipment	_	- `		-	-			_	31,030	37,030
Total expenditures				247,776	247,776				356,232	356,232
rotal experientales				247,770	241,110				330,232	330,232
Excess (deficiency) of revenues over										
(under) expenditures				462,298	462,298				380,500	380,500
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	1,671,812	1,637,613	1,916,847	10,226,272	5,000,000	2,500,000	654,251	1,586,859	9,741,110
Fleviously Reported	3,000,000	1,071,012	1,037,013	1,910,047	10,220,272	3,000,000	2,300,000	034,231	1,500,059	3,741,110
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	5,000,000	1,671,812	1,637,613	1,916,847	10,226,272	5,000,000	2,500,000	654,251	1,586,859	9,741,110
as residieu	3,000,000	1,071,012	1,007,013	1,810,047	10,220,272	3,000,000	2,300,000	004,201	1,000,009	3,141,110
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 1,671,812	\$ 1,637,613	\$ 2,379,145	\$ 10,688,570	\$ 5,000,000	\$ 2,500,000	\$ 654,251	\$ 1,967,359	\$ 10,121,610
·			=====							

Page											
Endowment											
Contribution Revenue Society S											
Non-state matching funds \$. \$. \$. \$. \$. \$. \$. \$. \$. 343,078 343,078 343,078 Total contribution revenue		Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Investment Income Realized gain (loss)	Contribution Revenue										
Investment Income	Non-state matching funds	\$ -		\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 343,078	\$ 343,078
Realized gain (loss)	Total contribution revenue					•				343,078	343,078
Realized gain (loss)											
Contractual Charges					4 000 000					1 000 110	4 000 440
Formal Endowment Income		-	-	-	, ,		-	-	-		
Total investment income (loss) - - 597.753 597.753 - - 668,825 668,825 Total revenue - 597.753 597.753 - - 1,011,903 1,011,903 Expenditures - 597.753 597.753 - - 1,011,903 1,011,903 Expenditures - 147.832 147.832 - - 53,642 558,642 <t< td=""><td>9 , ,</td><td>-</td><td>-</td><td>-</td><td></td><td></td><td>-</td><td>-</td><td>-</td><td></td><td>, , ,</td></t<>	9 , ,	-	-	-			-	-	-		, , ,
Total revenue S97,753											
Expenditures	Total investment income (loss)				597,753	597,753				668,825	668,825
Personal services	Total revenue				597,753	597,753				1,011,903	1,011,903
Personal services	Expenditures										
Fringe	•	_	_	_	147 832	147 832		_	_	53 642	53 642
Travel		_	_	_				_	_		,
Subrecipients Supplies Supplie		_	_	_				_	_		,
Supplies		_	_		0,070	0,070	_	_	_		2,002
Contractual 74,662 74,662 97,887 97,887 Other	•				30.472	30 472					17/ /75
Other - - 8,161 8,161 - - 39,986 38,986 Fixed Charges - - - 10,321 10,321 - - 12,711 12,711 Professional & Other Fees - - - 1,500 1,500 - - - 6,610 6,610 Equipment - - - 16,254 16,254 - - - 5,395 5,395 Total expenditures - - - 347,245 347,245 - - - 411,412 411,412 Excess (deficiency) of revenues over (under) expenditures - - - 250,508 - - - 600,491 600,491 Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Fund Balance - June 30, 2017, - - -	• •		_				_		_		
Fixed Charges					,					,	,
Professional & Other Fees											·
Equipment	J	-					-	-	-		·
Total expenditures - - 347,245 347,245 - - 411,412 411,412 Excess (deficiency) of revenues over (under) expenditures - - - 250,508 - - - 600,491 Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Fund Balance - June 30, 2017, - </td <td></td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td>		-	-				-	-	-		
Excess (deficiency) of revenues over (under) expenditures 250,508 250,508 600,491 600,491 Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Fund Balance - June 30, 2017,	• •										
Cumulative Program Fund Balances - - - - - - - - - - - - - - 600,491 Cumulative Program Fund Balances Beginning Fund Balances as 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Prior Period Adjustment -	rotal expellultures				347,243	347,245	<u>-</u>			411,412	411,412
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Prior Period Adjustment -	Excess (deficiency) of revenues over										
Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Prior Period Adjustment -	(under) expenditures			<u>.</u>	250,508	250,508				600,491	600,491
Beginning Fund Balances as Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Prior Period Adjustment -	Cumulativa Program Fund Ralances										
Previously Reported 5,000,000 1,413,707 967,517 1,422,324 8,803,548 5,000,000 1,541,536 1,576,255 998,132 9,115,923 Prior Period Adjustment -											
Prior Period Adjustment -	0 0	5 000 000	4 440 707	007.547	4 400 004	0.000.540	F 000 000	4 544 500	4 570 055	000.400	0.445.000
Fund Balance - June 30, 2017,	Previously Reported	5,000,000	1,413,707	967,517	1,422,324	8,803,548	5,000,000	1,541,536	1,576,255	998,132	9,115,923
	Prior Period Adjustment										
	Fund Balance - June 30, 2017										
as restated 5,000,000 1,415,707 507,517 1,422,324 0,000,000 1,041,330 1,040,233 990,132 3,110,323		5 000 000	1 /13 707	067 517	1 422 324	8 803 549	5 000 000	1 5/1 526	1 576 255	008 132	9 115 922
	as restateu	3,000,000	1,413,707	301,311	1,422,324	0,003,540	3,000,000	1,041,000	1,370,233	330,132	3,110,323
Fund Balance - June 30, 2018 \$ 5,000,000 \$ 1,413,707 \$ 967,517 \$ 1,672,832 \$ 9,054,056 \$ 5,000,000 \$ 1,541,536 \$ 1,576,255 \$ 1,598,623 \$ 9,716,414	Fund Balance - June 30, 2018	\$ 5,000,000	\$ 1,413,707	\$ 967,517	\$ 1,672,832	\$ 9,054,056	\$ 5,000,000	\$ 1,541,536	\$ 1,576,255	\$ 1,598,623	\$ 9,716,414

		Advan	iced Tissue Biofab	orication			Medic	cation Safety and	Efficacy	_
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue					-		-			
Investment Income										
Realized gain (loss)	_	_	_	1,342,341	1,342,341	_	_	_	521,997	521,997
Unrealized gain (loss)	_	_	_	(772,056)	(772,056)	_	_	_	(298,282)	(298,282)
Endowment income	_	_	_	61,686	61,686	_	_	_	24,090	24,090
Total investment income (loss)				631,971	631,971	-			247,805	247,805
Total revenue				631,971	631,971				247,805	247,805
Expenditures										
Personal services	_	_	_	101,562	101,562	_	_	_	10,862	10,862
Fringe	_	_	_	35,299	35,299		_	_	3,055	3,055
Travel	_	_	_	858	858		_	_	10,302	10,302
Subrecipients	_	_				_	_	_	-	,
Supplies	_	_		2,036	2,036	_	_	_	2,335	2,335
Contractual	_	_	-	78,935	78,935	_	_	_	25,246	25,246
Other	_	_	_	638	638	_	_	_	22	22
Fixed Charges	_	-/	_	2,385	2,385	_	_	_	_	-
Professional & Other Fees	_	-			_	_	_	_	82,320	82,320
Equipment	_	_ `	4			-	-	_	-	-
Total expenditures				221,713	221,713				134,142	134,142
Excess (deficiency) of revenues over										
(under) expenditures				410,258	410,258				113,663	113,663
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	1,200,000	75,000	1,634,170	7,909,170	2,000,000	600,000	203,232	428,227	3,231,459
Prior Period Adjustment		<u>.</u>		318,485	318,485				81,046	81,046
Fund Balance - June 30, 2017, as restated	5,000,000	1,200,000	75,000	1,952,655	8,227,655	2,000,000	600,000	203,232	509,273	3,312,505
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 1,200,000	\$ 75,000	\$ 2,362,913	\$ 8,637,913	\$ 2,000,000	\$ 600,000	\$ 203,232	\$ 622,936	\$ 3,426,168

		_	0 5:					5.0.1.1		
	04-4-	Non-State	state Cancer Dispa			Otata		cs, Pathobiology a		
	State			Endowment	Total	State	Non-State	Non-State	Endowment	Total
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue					-					<u> </u>
Investment Income										
Realized gain (loss)	-	-	-	954,886	954,886	-	-	-	1,648,048	1,648,048
Unrealized gain (loss)	-	-	-	(548,645)	(548,645)	-	-	-	(948,764)	(948,764)
Endowment income				43,829	43,829				75,735	75,735
Total investment income (loss)				450,070	450,070				775,019	775,019
Total revenue				450,070	450,070				775,019	775,019
- "										
Expenditures Personal services				88,478	88,478				129,167	129,167
	-	-	-			-	-	-		
Fringe Travel	-	-	-	26,138 84	26,138 84	-	-	-	47,320 417	47,320 417
	-	-		04	04	-	-	-	417	417
Subrecipients	-	-	•	17	17	-	-	-	40,287	40,287
Supplies Contractual	-	-	-	56,074	56,074	-	-	-	40,287 96,849	40,287 96,849
Other	-	-	-	3,865	3,865	-	-	-	90,049	30,049
Fixed Charges	-	-	-	286	286	-	-	-	18,194	- 18,194
Professional & Other Fees	-	-		2,162	2,162	-	-	-	250	250
Equipment	-	-		2,102	2,102	-	-	-	487	487
Total expenditures				177,104	177,104				332,971	332,971
rotal expenditures				177,104	177,104		<u>-</u>		332,971	332,971
Excess (deficiency) of revenues over										
(under) expenditures	- /			272,966	272,966	-	-	-	442,048	442,048
, , ,										
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	3,600,000	1,080,000	9,769	1,246,541	5,936,310	5,000,000	3,451,075	(118,779)	1,216,637	9,548,933
Drien Denied Adjustment										
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	3,600,000	1,080,000	9,769	1,246,541	5,936,310	5,000,000	3,451,075	(118,779)	1,216,637	9,548,933
	5,555,550	.,555,550	5,.00	.,2.0,011	-,,,,,,,,	5,555,566	5, .5.,510	(1.0,10)	.,2.0,001	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Fund Balance - June 30, 2018	\$ 3,600,000	\$ 1,080,000	\$ 9,769	\$ 1,519,507	\$ 6,209,276	\$ 5,000,000	\$ 3,451,075	\$ (118,779)	\$ 1,658,685	\$ 9,990,981

			ammation and Fibr					ional Biomedical I		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -		\$ 2,900	\$ 2,900	\$ -	\$ -	\$ -	\$ -	\$ -
Total contribution revenue				2,900	2,900					-
Investment Income							_			
Realized gain (loss)	-	-	-	1,455,232	1,455,232	-	-	-	500,272	500,272
Unrealized gain (loss)	-	-	-	(837,153)	(837,153)	-	-	-	(288,233)	(288,233)
Endowment income	-	-	-	66,856	66,856	-	-	-	22,995	22,995
Total investment income (loss)	-			684,935	684,935	_			235,034	235,034
Total revenue				687,835	687,835	-			235,034	235,034
Expenditures										
Personal services	_	_	_	116,675	116,675		_	_	106,777	106,777
Fringe	_	_	_	42,352	42,352		_	_	39,046	39,046
Travel	_	_	_	,			_	_	7,731	7,731
Subrecipients	_	_	115,000	-	115,000	_	_	_	· -	
Supplies	_	_	-	12,330	12,330	_	_	_	62	62
Contractual	-	_	-	85,714	85,714	_	-	-	29,380	29,380
Other	-	_	-	9,634	9,634	_	-	-	· -	
Fixed Charges	-	-				_	-	-	-	-
Professional & Other Fees	-	-	-	-		_	-	-	3,277	3,277
Equipment	-	- `	—	84	84	-	_	-	17,590	17,590
Total expenditures			115,000	266,789	381,789				203,863	203,863
Excess (deficiency) of revenues over										
(under) expenditures			(115,000)	421,046	306,046				31,171	31,171
Cumulative Program Fund Balances Beginning Fund Balances as										
Previously Reported	4,999,999	2,279,049	2,373,316	(811,658)	8,840,706	2,000,000	600,000	741,884	314,067	3,655,951
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	4,999,999	2,279,049	2,373,316	(811,658)	8,840,706	2,000,000	600,000	741,884	314,067	3,655,951
Fund Balance - June 30, 2018	\$ 4,999,999	\$ 2,279,049	\$ 2,258,316	\$ (390,612)	\$ 9,146,752	\$ 2,000,000	\$ 600,000	\$ 741,884	\$ 345,238	\$ 3,687,122

		Total - Medi	cal University of S	outh Carolina	
	State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue					
Non-state matching funds	\$ -	\$ -	\$ -	\$ 354,993	\$ 354,993
Total contribution revenue				354,993	354,993
Investment Income					
Realized gain (loss)	-	-	-	24,437,347	24,437,347
Unrealized gain (loss)	-	-	-	(13,575,293)	(13,575,293)
Endowment income	-	-	-	1,110,756	1,110,756
Total investment income (loss)	-			11,972,810	11,972,810
Total revenue				12,327,803	12,327,803
Total revenue				12,327,003	12,327,003
Expenditures					
Personal services	-	_	_	2,501,583	2,501,583
Fringe	-	_	_	858,957	858,957
Travel	-	_		81,387	81,387
Subrecipients	-	_	115,000	988	115,988
Supplies	-	_	-	468,443	468,443
Contractual	-	_	-	1,336,381	1,336,381
Other	-	_	_	302,953	302,953
Fixed Charges	-	-	-	64,139	64,139
Professional & Other Fees	-	-	-	311,741	311,741
Equipment	-	_	4	935,440	935,440
Total expenditures			115,000	6,862,012	6,977,012
Excess (deficiency) of revenues over (under) expenditures	_		(115,000)	5,465,791	5,350,791
(under) experialitares			(113,000)	3,403,731	3,330,731
Cumulative Program Fund Balances					
Beginning Fund Balances as					
Previously Reported	88,099,999	34,996,979	12,221,288	25,055,890	160,374,156
1 Toviously Reported	00,000,000	04,000,010	12,221,200	20,000,000	100,074,100
Prior Period Adjustment	-		-	506,560	506,560
Fund Balance - June 30, 2017,					
as restated	88,099,999	34,996,979	12,221,288	25,562,450	160,880,716
5 IBI I 00 00/5	* •••••••	A 04 000 0=0	A 10 100 000	* 04 000 0 : :	A 400 004 F
Fund Balance - June 30, 2018	\$ 88,099,999	\$ 34,996,979	\$ 12,106,288	\$ 31,028,241	\$ 166,231,507

			Nanostructures					Brain Imaging		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue	-	-	-	-	•	-	-	-	-	-
Total contribution revenue					-	-				
Investment Income										
Realized gain (loss)	-	-	-	71,159	71,159	-	-	-	90,491	90,491
Unrealized gain (loss)	-	-	-	193,585	193,585	-	-	-	243,151	243,151
Endowment income	-	-	-	32,267	32,267	_	-	-	25,739	25,739
Total investment income (loss)				297,011	297,011	<u> </u>			359,381	359,381
Total revenue				297,011	297,011	-			359,381	359,381
Expenditures										
Personal services	_	_	_	100,666	100,666		_	_	55,487	55,487
Fringe	_	_		18,112	18,112	_	_	_	2,123	2,123
Travel	_	_		8,696	8,696	_	_	_	520	520
Supplies	_	_		64,579	64,579	_	_	_	755	755
Tuition assistance	_	_	_	3,312	3,312	_	_	-	9,787	9,787
Administrative fees	_	_	-	21,284	21,284	_	_	_	27,066	27,066
Other	_	_	-	36,023	36,023	_	_	_	127,552	127,552
Equipment	_			174,409	174,409	_	_	_		
Total expenditures				427,081	427,081				223,290	223,290
Excess (deficiency) of revenues over										
(under) expenditures		<u> </u>		(130,070)	(130,070)				136,091	136,091
Transfers										
Cumulative Program Fund Balances										
Beginning Fund Balances as Previously Reported	4,000,000	1,631,274	-	1,145,625	6,776,899	5,000,000	2,102,769	-	324,616	7,427,385
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	4,000,000	1,631,274		1,145,625	6,776,899	5,000,000	2,102,769		324,616	7,427,385
Fund Balance - June 30, 2018	\$ 4,000,000	\$ 1,631,274	\$ -	\$ 1,015,555	\$ 6,646,829	\$ 5,000,000	\$ 2,102,769	\$ -	\$ 460,707	\$ 7,563,476

			lymer Nanocompo					Fuel Cell Economy		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ 500	\$ 8,000	\$ -	\$ 8,500	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue				25,000	25,000					
Total contribution revenue		500	8,000	25,000	33,500	-	-			-
Investment Income										
Realized gain (loss)	-	-	-	72,436	72,436	-	-	-	73,391	73,391
Unrealized gain (loss)	_	_	_	177,091	177,091	_	_	_	230,187	230,187
Endowment income	_	_	_	17,922	17,922	_	_	_	50,140	50,140
Total investment income (loss)	-			267,449	267,449	<u> </u>			353,718	353,718
Total revenue		500	8,000	292,449	300,949				353,718	353,718
Expenditures										
Personal services	_	_		143,321	143,321		_	_	106,732	106,732
Fringe	_	_		10,454	10,454		_	_	14,766	14,766
Travel	_	_	4,452	15,148	19,600	_	_	_	2,915	2,915
Supplies	_	_	1,388	21,902	23,290	_	_	_	1,070	1,070
Tuition assistance	_	_	3,000	13,530	16,530	_	_	_	-	-
Administrative fees	_	_	_	21,666	21,666	_	_	_	21,951	21,951
Other	_	-	_	38,556	38,556	_	_	_	32,711	32,711
Equipment	_	_	1,617	14,818	16,435	_	_	_	-	,
Total expenditures			10,457	279,395	289,852				180,145	180,145
Excess (deficiency) of revenues over										
(under) expenditures		500	(2,457)	13,054	11,097				173,573	173,573
Transfers				10,329	10,329					
Cumulative Program Fund Balances Beginning Fund Balances as	0.500.000	4 440 440	44.700	077.070	5.005.470	5 000 000	4 500 000		4 740 540	0.040.540
Previously Reported	3,500,000	1,442,412	14,782	377,979	5,335,173	5,000,000	1,500,000	-	1,718,549	8,218,549
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	3,500,000	1,442,412	14,782	377,979	5,335,173	5,000,000	1,500,000		1,718,549	8,218,549
Fund Balance - June 30, 2018	\$ 3,500,000	\$ 1,442,912	\$ 12,325	\$ 401,362	\$ 5,356,599	\$ 5,000,000	\$ 1,500,000	\$ -	\$ 1,892,122	\$ 8,392,122

			and Economic De					Renewable Fuel Co		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue	-	-	-	-	-	-	-	-	-	-
Total contribution revenue		-			-	-				
Investment Income										
Realized gain (loss)	_	-	-	57,693	57,693	-	-	_	66,977	66,977
Unrealized gain (loss)	_	_	_	113,557	113,557	_	_	_	155,505	155,505
Endowment income	_	_	_	17,482	17,482	_	_	_	16,619	16,619
Total investment income (loss)				188,732	188,732	-			239,101	239,101
Total revenue				188,732	188,732	-			239,101	239,101
Expenditures										
Personal services	_	_	_	43,870	43,870		_	_	141,819	141,819
Fringe	_	_		11,028	11,028		_	_	10,987	10,987
Travel	_	_		18,449	18,449	_	_	_	18,237	18,237
Supplies	_	_		5,276	5,276	_	_	_	67,366	67,366
Tuition assistance	_	_	_	20,157	20,157	_	_	_	9,939	9,939
Administrative fees	_	_	_	17,256	17,256	_	_	_	20,033	20,033
Other	_	_		3,258	3,258	_	_	_	18,018	18,018
Equipment	_	_		3,233	0,200	_	_	_	62	62
Total expenditures				119,294	119,294				286,461	286,461
Excess (deficiency) of revenues over										
(under) expenditures				69,438	69,438				(47,360)	(47,360)
Transfers									(10,329)	(10,329)
Cumulative Program Fund Balances Beginning Fund Balances as										
Previously Reported	2,000,000	1,410,000	87	320,423	3,730,510	3,000,000	1,200,000	-	529,617	4,729,617
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	2,000,000	1,410,000	87	320,423	3,730,510	3,000,000	1,200,000		529,617	4,729,617
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 1,410,000	\$ 87	\$ 389,861	\$ 3,799,948	\$ 3,000,000	\$ 1,200,000	\$ -	\$ 471,928	\$ 4,671,928

			olid Oxide Fuel Co					thood Neurothera		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue										
Total contribution revenue		<u> </u>			-	-				
Investment Income										
Realized gain (loss)	-	-	-	5,396	5,396	-	-	-	130,996	130,996
Unrealized gain (loss)	-	-	-	136,746	136,746	-	-	-	273,859	273,859
Endowment income	-	-	-	10,519	10,519	-	-	-	33,838	33,838
Total investment income (loss)	-			152,661	152,661	-			438,693	438,693
Total revenue				152,661	152,661	-			438,693	438,693
Expenditures										
Personal services	-	-	-	43,177	43,177		-	_	270,273	270,273
Fringe	-	-		6,496	6,496		-	_	47,036	47,036
Travel	-	-	-	7,012	7,012	-	-	-	8,422	8,422
Supplies	-	-	-	18,171	18,171	-	-	-	3,509	3,509
Tuition assistance	-	-	-	-		-	-	-	1,531	1,531
Administrative fees	-	-	-	1,614	1,614	-	-	-	39,181	39,181
Other	-	-	-	22,923	22,923	-	-	-	79,700	79,700
Equipment	-	-	-	33,066	33,066	-	-	-	-	-
Total expenditures				132,459	132,459				449,652	449,652
Excess (deficiency) of revenues over (under) expenditures	_			20,202	20,202	_	_	_	(10,959)	(10,959)
· , .			$\overline{}$						(::,:::)	(10,000)
Transfers	_		-	<u> </u>	-					
Cumulative Program Fund Balances Beginning Fund Balances as										
Previously Reported	3,000,000	900,000	-	378,307	4,278,307	5,000,000	2,502,066	-	997,641	8,499,707
Prior Period Adjustment		·							60,785	60,785
Fund Balance - June 30, 2017,										
as restated	3,000,000	900,000		378,307	4,278,307	5,000,000	2,502,066		1,058,426	8,560,492
Fund Balance - June 30, 2018	\$ 3,000,000	\$ 900,000	\$ -	\$ 398,509	\$ 4,298,509	\$ 5,000,000	\$ 2,502,066	\$ -	\$ 1,047,467	\$ 8,549,533

	State	Non-State	Non-State	Endowment	· ,	State	Non-State	nes to Electricity F Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	¢	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue	Ψ -	Ψ -	Ψ -	Ψ -	,	- ч	Ψ	7,728	Ψ -	7,728
Total contribution revenue	<u>-</u>							7,728	<u> </u>	7,728
Total contribution revenue								1,120		1,120
Investment Income										
Realized gain (loss)	_	_	_	78,399	78,399	_	_	_	120,596	120,596
Unrealized gain (loss)	_	_	_	233,984	233,984		_	_	265,975	265,975
Endowment income	_	_	11,475	20,967	32,442		_	_	38,675	38,675
Total investment income (loss)			11,475	333,350	344,825	-			425,246	425,246
` ,										
Total revenue			11,475	333,350	344,825			7,728	425,246	432,974
Expenditures										
Personal services				318,764	318,764			3,719	204,718	208,437
Fringe				53,405	53,405			3,7 13	16,105	16,105
Travel	_	_		37,915	37,915	_	_	705	10,418	11,123
Supplies	_	_		11,365	11,365	_	_	9,896	8,423	18,319
Tuition assistance	_	_		28,145	28,145	_	_	5,050	24,021	24,021
Administrative fees	_	_		23,449	23,449	_	_	_	36,070	36,070
Other	_	_		366,276	366,276	_	_	41,421	3,578	44,999
Equipment	_			3,293	3,293	_	_	71,721	75,302	75,302
Total expenditures			-	842,612	842,612			55,741	378,635	434,376
Excess (deficiency) of revenues over			44.475	(509,262)	(497,787)			(48,013)	46,611	(4.400
(under) expenditures			11,475	(509,262)	(497,767)			(46,013)	40,011	(1,402
Transfers										
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	5,000,000	1,500,000	1,525,726	959,971	8,985,697	5,000,000	2,515,000	68,845	1,296,695	8,880,540
, ,					, ,					, ,
Prior Period Adjustment		-								
Fund Balance - June 30, 2017,										
as restated	5,000,000	1,500,000	1,525,726	959,971	8,985,697	5,000,000	2,515,000	68,845	1,296,695	8,880,540
as restated	3,000,000	1,500,000	1,020,120	303,311	0,303,037	5,000,000	2,010,000	00,043	1,230,093	0,000,040
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 1,500,000	\$ 1,537,201	\$ 450,709	\$ 8,487,910	\$ 5,000,000	\$ 2,515,000	\$ 20,832	\$ 1,343,306	\$ 8,879,138

			Healthcare Quality					enior SMART [™] Cei	nter	
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue					-					
Total contribution revenue					-	-				
Investment Income										
Realized gain (loss)	-	-	-	104,654	104,654	-	-	-	92,505	92,505
Unrealized gain (loss)	-	-	-	253,888	253,888	-	-	-	244,677	244,677
Endowment income	-	-	-	35,963	35,963	-	-	-	29,900	29,900
Total investment income (loss)				394,505	394,505				367,082	367,082
Total revenue				394,505	394,505	-			367,082	367,082
Expenditures										
Personal services	-	-	-	183,670	183,670		-	-	84,934	84,934
Fringe	-	-		30,821	30,821	-	-	-	11,782	11,782
Travel	-	-	-	17,822	17,822	-	-	-	7,963	7,963
Supplies	-	_	-	8,704	8,704	-	_	2,395	12,719	15,114
Tuition assistance	-	-	-	15,673	15,673	-	-	-	-	-
Administrative fees	-	-	-	31,302	31,302	-	-	-	27,668	27,668
Other	-	-	- ,	138,589	138,589	-	-	800	85,778	86,578
Equipment	-	-	-	7,428	7,428	-	-	-	6,727	6,727
Total expenditures				434,009	434,009			3,195	237,571	240,766
Excess (deficiency) of revenues over (under) expenditures	_			(39,504)	(39,504)	-	_	(3,195)	129,511	126,316
Transfers				_						
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported	5,000,000	2,000,000		1,203,511	8,203,511	5,000,000	2,000,000	29,955	750,005	7,779,960
	2,223,223	2,111,111		1,200,011	-,,	2,222,222	_,,			1,112,222
Prior Period Adjustment		-	-							
Fund Balance - June 30, 2017,	5,000,000	2,000,000		1 202 514	8,203,511	5,000,000	2,000,000	29,955	750,005	7,779,960
as restated	5,000,000	2,000,000	<u> </u>	1,203,511	<u></u>	5,000,000	2,000,000	29,955	750,005	7,779,960
Fund Balance - June 30, 2018	\$ 5,000,000	\$ 2,000,000	\$ -	\$ 1,164,007	\$ 8,164,007	\$ 5,000,000	\$ 2,000,000	\$ 26,760	\$ 879,516	\$ 7,906,276

			ntal Research and					lear Science and E		
	State	Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue				12,328	12,328					
Total contribution revenue	<u> </u>			12,328	12,328	-	-			
Investment Income										
Realized gain (loss)	-	-	_	56,575	56,575	-	_	-	47,561	47,561
Unrealized gain (loss)	-	-	_	147,619	147,619	_	_	-	140,785	140,785
Endowment income	-	-	_	16,259	16,259	_	_	-	16,789	16,789
Total investment income (loss)			-	220,453	220,453	·	_		205,135	205,135
Total revenue				232,781	232,781	-			205,135	205,135
Expenditures										
Personal services	_	_	_	177,722	177,722		_	_	222,432	222,432
Fringe	-	-		19,426	19,426		_	-	20,502	20,502
Travel	_	_		26,690	26,690	_	_	_	8,599	8,599
Supplies	_	_	-	27,791	27,791	_	_	_	· -	· -
Tuition assistance	-	-	-	8,380	8,380	-	_	-	-	-
Administrative fees	-	-	-	16,922	16,922	-	_	-	14,225	14,225
Other	-	-/	_	39,994	39,994	-	_	-	· -	, , , , , , , , , , , , , , , , , , ,
Equipment	_	-				_	_	_	_	-
Total expenditures				316,925	316,925				265,758	265,758
Excess (deficiency) of revenues over				(24.44)	(0.1.1.1)				(00,000)	(00.000)
(under) expenditures		<u> </u>	\rightarrow	(84,144)	(84,144)				(60,623)	(60,623)
Transfers			<u> </u>	<u> </u>						-
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported	3,000,000	1,000,000		545,868	4,545,868	3,000,000	905,000	_	594,450	4,499,450
1 Totaday Reported	0,000,000	1,000,000		040,000	4,040,000	0,000,000	300,000	_	557,750	4,400,400
Prior Period Adjustment										
Fund Balance - June 30, 2017,										
as restated	3,000,000	1,000,000		545,868	4,545,868	3,000,000	905,000		594,450	4,499,450
Fund Balance - June 30, 2018	\$ 3,000,000	\$ 1,000,000	\$ -	\$ 461,724	\$ 4,461,724	\$ 3,000,000	\$ 905,000	•	\$ 533,827	\$ 4,438,827

	State								es	
		Non-State	Non-State	Endowment		State	Non-State	Non-State	Endowment	
-	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
· · · · · · · · · · · · · · · · · · ·	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 3,120	\$ -	\$ -	\$ 3,120
Other Contributions/Revenue	-									
Total contribution revenue					-	<u> </u>	3,120			3,120
Investment Income										
Realized gain (loss)	-	-	_	65,643	65,643	-	-	_	23,993	23,993
Unrealized gain (loss)	-	_	_	154,494	154,494	-	-	_	122,842	122,842
Endowment income	_	_	_	27,632	27,632	_	_	_	16,046	16,046
Total investment income (loss)	-			247,769	247,769	-			162,881	162,881
Total revenue				247,769	247,769		3,120		162,881	166,001
Expenditures										
Personal services	-	_	_	30,770	30,770		-	_	20,000	20,000
Fringe	_	_		741	741		_	_	362	362
Travel	_	_	_	8,050	8,050	-	_	_	_	-
Supplies	-	_		11,619	11,619	_	_	_	1,325	1,325
Tuition assistance	-	_	-	-	,	_	_	_	-	-,
Administrative fees	_	_		19,634	19,634	_	_	_	7,180	7,180
Other	_	-		1,524	1,524	_		_	46,444	46,444
Equipment	_	_	_	1,021	.,02.	_	_	_	-	,
Total expenditures	-		•	72,338	72,338				75,311	75,311
Excess (deficiency) of revenues over										
(under) expenditures	-	_		175,431	175,431		3,120		87,570	90,690
Transfers										
Cumulative Program Fund Balances Beginning Fund Balances as Previously Reported	3,000,000	1,410,000	_	637,265	5,047,265	3,000,000	458,040	_	512,067	3,970,107
-9	2,222,200	.,,,,,,,		22.,200	-, ,- 20	-,,	122,210		,50.	-, 3,
Prior Period Adjustment	-		_							
Fund Balance - June 30, 2017, as restated	3,000,000	1,410,000		637,265	5,047,265	3,000,000	458,040		512,067	3,970,107
Fund Balance - June 30, 2018	\$ 3,000,000	\$ 1,410,000	Φ	\$ 812,696	\$ 5,222,696	\$ 3,000,000	\$ 461,160	•	\$ 599,637	\$ 4,060,797

	State	Non-State	imulation, Imaging Non-State	Endowment	<u>:</u>	State	Multiphysics Heter Non-State	Non-State	Endowment	
	Endowment	Endowment	Expendable	Earnings	Total	Endowment	Endowment	Expendable	Earnings	Total
Contribution Revenue										
Non-state matching funds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Other Contributions/Revenue	·	-	· -	_	•	· -	· .	_		٠.
Total contribution revenue										
Investment Income										
Realized gain (loss)	_	_	_	77,350	77,350	_	_	_	179,365	179,365
Unrealized gain (loss)	_	_	_	128,461	128,461		_	_	205,803	205,803
Endowment income	_	_	_	33,195	33,195	_	_	_	44,150	44,150
Total investment income (loss)		-		239,006	239,006				429,318	429,318
Total revenue				239,006	239,006	-			429,318	429,318
Expenditures										
Personal services	_	_	_	61,596	61,596		_	_	68,000	68,000
Fringe	_	_	_	14,822	14,822	_	_	_	10,038	10,038
Travel	_	_		27,495	27,495	_	_	_	1,526	1,526
Supplies	_	_		8,976	8,976	_	_	_	5,298	5,298
Tuition assistance	_	_	_		5,575	_	_	_	9,289	9,289
Administrative fees	_	_	_	23,135	23,135	_	_	_	53,648	53,648
Other	_			13,189	13,189	_	_	_	5	5
Equipment	_			10,100	10,100	_	_	_	98,606	98,606
Total expenditures				149,213	149,213				246,410	246,410
Excess (deficiency) of revenues over				00.700					400.000	400.000
(under) expenditures		_	\rightarrow	89,793	89,793				182,908	182,908
Transfers				<u>.</u>						
Cumulative Program Fund Balances										
Beginning Fund Balances as										
Previously Reported	2,000,000	1,582,098		1,243,645	4,825,743	2,000,000	3,750,000	_	510,169	6,260,169
	_,,	1,002,000		,,,	.,,	_,,	2,122,222		2.2,.22	-,,
Prior Period Adjustment		-								
Fund Belones Itune 00, 0047										
Fund Balance - June 30, 2017,	0.000.000	4 500 000		4.040.0:-	4.00==:0	0.000.000	0.750.000		E40.400	
as restated	2,000,000	1,582,098		1,243,645	4,825,743	2,000,000	3,750,000		510,169	6,260,169
Fund Balance - June 30, 2018	\$ 2,000,000	\$ 1,582,098	\$ -	\$ 1,333,438	\$ 4,915,536	\$ 2,000,000	\$ 3,750,000	\$ -	\$ 693,077	\$ 6,443,077
i unu balance - June 30, 2010	Ψ 2,000,000	ψ 1,562,096	Ψ -	ψ 1,000,400	ψ 4,310,03 0	Ψ ∠,000,000	φ 3,730,000	Ψ -	ψ 093,077	Ψ 0,443,077

	Total - University of South Carolina								
	State	Non-State	Non-State	Endowment					
	Endowment	Endowment	Expendable	Earnings	Total				
Contribution Revenue									
Non-state matching funds	\$ -	\$ 3,620	\$ 8,000	\$ -	\$ 11,620				
Other Contributions/Revenue	· -	-	7,728	37,328	45,056				
Total contribution revenue		3,620	15,728	37,328	56,676				
Investment Income									
Realized gain (loss)	_	_	_	1,415,180	1,415,180				
Unrealized gain (loss)		_		3,422,209	3,422,209				
Endowment income	_	_	11,475	484,102	495,577				
Total investment income (loss)			11,475	5,321,491	5,332,966				
Total revenue	_	3,620	27,203	5,358,819	5,389,642				
Total Tevende		0,020	21,200	0,000,010	0,000,042				
Expenditures									
Personal services	-	-	3,719	2,277,951	2,281,670				
Fringe	-	-		299,006	299,006				
Travel	-	-	5,157	225,877	231,034				
Supplies	-	-	13,679	278,848	292,527				
Tuition assistance	-	-	3,000	143,764	146,764				
Administrative fees	-	-	-	423,284	423,284				
Other	-	-	42,221	1,054,118	1,096,339				
Equipment			1,617	413,711	415,328				
Total expenditures			69,393	5,116,559	5,185,952				
Excess (deficiency) of revenues over									
(under) expenditures		3,620	(42,190)	242,260	203,690				
Transfers					-				
Cumulative Program Fund Balances				*					
Beginning Fund Balances as									
Previously Reported	66,500,000	29,808,659	1,639,395	14,046,403	111,994,457				
Prior Period Adjustment				60,785	60,785				
Fund Balance - June 30, 2017,									
as restated	66,500,000	29,808,659	1,639,395	14,107,188	112,055,242				
			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
Fund Balance - June 30, 2018	\$ 66,500,000	\$ 29,812,279	\$ 1,597,205	\$ 14,349,448	\$ 112,258,932				